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ABSTRACT
Microangiopathy is a major cause of morbidity and mortality in diabetes mellitus,
and its pathogenesis remains poorly understood. Abnormalities of both in vivo and
in vitro haemostasis have been extensively reported, particularly changes in
platelet function have been described in cross-sectional studies, and cause-end-
effect relationships have been postulated. It is also suggested that neutrophil
accumulation at sites of inflammation, including vascular endothelium, can induce
tissue damage. Three classes of mediators are particularly likely to participate in
the pathogenesis of neutrophil-mediated vascular injury : granule enzymes,
reactive oxygen metabolites, and products of membrane phospholipids.
The aims of this thesis were to investigate changes in platelet function in insulin-
dependent diabetic patients in relation to glycaemic control, and microvascular
disease in the form of retinopathy. In addition, the changes in platelet function in
non-insulin-dependent diabetic patients at diagnosis, and the effect of glycaemic
control and oral hypoglycaemic therapy were assessed. As a measure of neutrophil
activity, neutrophil elastase was measured in insulin-dependent diabetic patients
with retinopathy. The changes in elastase levels in response to acute insulin-
induced hypoglycaemia in non-diabetic subjects were also evaluated. A further aim
was to measure a marker for free radical activity in insulin-dependent diabetes.
The changes in platelet density, thromboxane production and receptor sensitivity
demonstrated are consistent with platelets from diabetic patients being
hyperaggregable and contributing towards microvascular disease. The increase in
neutrophil elastase levels in insulin-dependent diabetic patients, and the rise in
normals in response to hypoglycaemia are consistent with leucocyte-endothelial
interaction contributing towards diabetic vascular disease. Although, the marker
for free radical activity was not increased in the retinopathic insulin-dependent
diabetic patients studied, it is probable that abnormalities of lipid metabolism
related to free radical activity may still contribute to diabetic vascular disease.
Although good glycaemic control can delay the onset and slow the progress of diabetic
complications, specific therapeutic agents that interfere with haemostasis,
leucocyte function and free radical activity may also have a protective role in the
development of diabetic complications. In addition, use of these agents may also give
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1.4 Free radical activity
1.5 Aims
1.1 Introduction
The introduction of insulin in 1922 was one of the great achievements of 20th
century medicine; it provided a lifesaving remedy for many diabetic patients and
led to a new era for diabetes. However, although many of the features of diabetic
complications had been described well before the introduction of insulin it was not
until patients survived for longer periods that their full extent and often fatal
nature was realised. It was only in 1954 that Lundbaek introduced the concept of
diabetic angiopathy (a specific widespread diabetic small vessel disease) as the
common mechanism leading to diabetic complications.
Vascular disease remains the most common cause of morbidity in the diabetic
population (Robertson and Strong, 1968). The pathogenesis of both
macrovascular and microvascular disease in diabetes mellitus remains poorly
understood. Macrovascular disease may present in the form of a thrombo-embolic
event like myocardial infarction, peripheral vascular disease and cardiovascular
disease. It often occurs earlier and advances more rapidly in diabetic patients
than in the general population (Kannel and McGee, 1979; Ganda, 1980). Small
vessel disease is unique to diabetes. Thickening of the basement membrane,
microthrombosis and endothelial proliferation are the main pathogenic features,
while the complications caused by microvascular disease include retinopathy,
renal disease and possibly polyneuropathy.
1.2 Platelets
Abnormalities of both in vivo and in vitro haemostasis have been extensively
reported in diabetes (Jones et al, 1981; Colwell et al, 1983). Particularly,
changes in platelet function have been described in cross-sectional studies of
diabetic animals and patients, and cause-and-effect relationships have been
postulated. The association of platelet and other haemostatic abnormalities which
favour platelet deposition and thrombosis formation in diabetes can be interpreted
in many ways. First, the abnormalities could contribute directly to the diabetic
vascular disease; second, they could be totally unrelated; third, diabetic vascular
disease could cause the defects; and fourth, they could be contributory to, and
result from the vascular disease (Colwell et al, 1983).
The evidence that platelets have a role to play in the development of diabetic
vascular disease is derived at least in part from the presence of platelet
abnormalities prior to histological evidence of vascular disease (Sagel et al,
1975; Halushka et al, 1981; Paulsen et al, 1981; Janka and Demmel, 1981).
Further evidence is provided by the alteration in haemostatic factors with
improvement of glycaemic control (Janka and Demmel, 1981; Juhan et al, 1982;
Hiramatsu et al,1987), the detection of platelet microthrombi in experimental
diabetes (Bloodworth and Moliter, 1965; Ishibashi et al, 1981) and reports of
diminished rate of progression of diabetic vascular disease with the use of non¬
steroidal anti-inflammatory drugs (Powell and Field, 1964; Colwell et al, 1986;
Donadio et al, 1988; The Damad Study Group, 1989).
1.3 Leucocytes
Many investigators have proposed a causal relationship between neutrophil
accumulation at sites of inflammation and subsequent tissue changes, including
local oedema, haemorrhage and thrombosis. As long ago as 1887, Metchnikoff
postulated that during intracellular killing and digestion of phagocytosed bacteria,
neutrophils may release substances extracellularly that damage vessel walls.
However, the first convincing evidence for a critical role for neutrophils in
vascular injury came from studies in the 1950's and 1960's using animals
depleted of circulating neutrophils by specific antibody or nitrogen mustard.
Neutrophil depletion prevented immune-mediated vascular injury in the Arthus
reaction, serum sickness, and nephritis (Cochrane and Janoff, 1975).
Neutrophils have also been shown to be necessary for the increase in vascular
permeability and tissue oedema induced by intradermal injection of chemotactic
agents (Wedmore and Williams, 1981; Issekutz, 1981). Neutrophils have been
particularly implicated in the development of respiratory distress syndrome
(Cochrane et al, 1983) and in several models, acute lung injury has been
attenuated by prior neutrophil depletion (Tate and Repine, 1983). It is
reasonable to hypothesize that in certain circumstances, neutrophils adherent to
the vessel wall release toxic products that damage endothelium or alter endothelial
function. Three classes of mediators are particularly likely to participate in the
pathogenesis of neutrophil-mediated vascular injury: granule enzymes, reactive
oxygen metabolites, and products of membrane phospholipids (Harlan, 1985;
Epstein, 1989).
Numerous abnormalities of neutrophil function have been described in diabetic
patients. An elevated plasma glucose concentration inhibits neutrophil function
and movement (Mowat and Baum, 1976; Molenaar et al, 1976), phagocytosis
(Bagdade et al, 1974), killing (Nolan et al, 1978), and oxidative metabolism
(Nath et al, 1984). In addition, oxidative killing by neutrophils from patients
with diabetes is inhibited by B-hydroxybutyrate and galactose (Wilson et al,
1987), and this is considered to be secondary to induced changes in the polyol
pathway due to an alteration in the redox potential.
1.4 Free radical activity
A free radical is an atom, ion or molecule with one or more unpaired electrons.
This configuration leads to an increased reactivity with other molecules. The
amount of reactivity depends on the ease with which a species can accept (is
reduced) or donate (is oxidised) electrons.
During aerobic metabolism molecular oxygen (O2) acts as the terminal electron
acceptor and undergoes stepwise reduction to water. Oxygen is a bi-radical : it has
two unpaired electrons in separate, parallel orbits both spinning in the same
direction. Non-radical species have paired electrons spinning in opposite
directions. One of these must spin invert before both can be accepted by oxygen.
This process can occur, but limits the reactivity of molecular oxygen, which
preferentially accepts electrons one at a time (univalent reduction). The
univalent reduction of oxygen produces the superoxide anion radical O2'
i.e. O2 + e'" — O2'" ('= unpaired electron and signifies a free radical).
The superoxide anion is comparatively unreactive. It has a very short half-life
and its solubility in lipids is low. These properties limit its capacity to diffuse
away from its site of generation and to affect cell membrane. In an ischaemic
environment with acid pH, the anion will become pronated forming the more
reactive perhydroxyl radical (HO'2). As this radical is uncharged, and therefore
more lipophilic, it can damage cell membranes.
In addition, because of its electronic configuration the superoxide anion can act
both as a reducing agent and an oxidising agent, thereby allowing transition metal
ions to act as catalysts in other free radical reactions. Further univalent
reduction of the superoxide anion yields a non-radical species (O22), which
exists at physiological pH in its pronated form, hydrogen peroxide (H2O2). This
species can diffuse a considerable distance and can cause damage via its reduction
to the hydroxyl radical (OH-). This reaction requires a transition metal ion such
as ferrous ion as a catalyst.
H202 + Fe2+ — OH" + OH" + Fe3+
The hydroxyl radical (OH') is extremely reactive and has a very short half-life;
thus its damaging effects are very localised.
By virtue of their unpaired electrons, superoxide, hydrogen peroxide and
hydroxyl radical react with virtually all cell components, especially
sulphhydryl-containing amino acids and unsaturated fatty acids. The potential
consequences of unimpeded free-radical reactions include the denaturation of
proteins, oxidation and peroxidation of membrane lipids, generation of
chemotactic factors, and impairment of collagen synthesis leading to loss of
enzyme activity, disturbed membrane permeability, and increased inflammatory
cell infiltration (Dormandy, 1983; McCord, 1985; Oberlay, 1988). As a
result, free radical activity has been implicated in inflammation, aging, malignant
change, alcohol-induced tissue damage (Dormandy, 1983; Fink et al, 1985) and
recently vascular damage associated with myocardial ischaemia and infarction
(Werns et al, 1986; Simpson et al, 1987). However, endogenous antioxidant
defence mechanisms may play an important role in limiting oxidant-mediated
vascular disease (Harlan et al, 1984), and alterations in their plasma and tissue
concentrations are thought to reflect changes in free radical activity (McCord and
Fridovich, 1977; Dormandy, 1983).
1.5 Aims
The pathogenesis of vascular disease in diabetes is poorly understood. Platelet
abnormalities have been extensively investigated, and mainly through
pharmacological manipulations, many abnormalities have been elucidated.
Although both neutrophil elastase and free radical activity have been implicated in
vascular disease, their roles in the development of diabetic microvascular disease
have not been clearly assessed.
The work in this thesis has been concerned with platelet and leucocyte functional
abnormalities, and also in changes in free radical activity in diabetic patients.
The experimental section is divided into two main parts. The first part (section
B) deals with platelet changes in insulin-dependent diabetic patients in relation to
glycaemic control, proliferative retinopathy and improvement in glycaemic
control. It also deals with changes in platelet parameters in non-insulin
dependent diabetic patients at diagnosis, and assesses the effect of glycaemic
control and oral hypoglycaemic therapy. The second section (section C)
investigates changes in neutrophil elastase in relation to microvascular disease,
and acute insulin-induced hypoglycaemia. In addition, this section is also


















Platelets have been extensively investigated during the past decade. The enormous
amount of interest stems from the awareness of the roles that platelets play not
only in haemostasis and thrombosis, but also, albeit less definitively, in
atherogenesis and arterial spasm (Ross and Glomset, 1976; Ganda, 1980; Ross,
1986). Platelets form a human tissue that can be readily and repeatedly sampled.
Furthermore, they can also act as a model for investigating stimulus-response
coupling pathways that can be expected to have general implications for other cell
types.
Platelets are very rapidly activated at sites of vascular injury and in fractions of a
second they begin adhering to the damaged area. Receptors for fibrinogen, which is
present in blood in large amounts, appear on the surface of the platelets and
fibrinogen forms cell-cell bridges so that others attach to those already present to
form the beginnings of a thrombus or platelet clump (Mustard et al, 1975). The
platelets also undergo a shape change, becoming more spherical and putting out long
pseudopodia. The contents of various classes of secretory granules are discharged
by secretory exocytosis, and contents include serotonin (5HT) and adenosine-5'-
16
diphosphate (ADP) which can stimulate activation of other platelets.
2.2 Platelet Morphology
Platelets are anucleate cytoplasmic fragments originating from megakaryocytes in
bone marrow. They circulate as biconvex discs (2-4um;7-8fl volume) and do not
normally adhere to other platelets, endothelium or other blood cells. A platelet can
be divided into four distinct regions: the peripheral zone, sol-gel zone, organelle
zone and membrane systems.
2.2.1 Peripheral zone
The peripheral zone constitutes the platelet wall and invaginates extensively into
the interior of the cell to form an open canalicular system. It maintains platelet
integrity, provides receptor sites for various stimulating or inhibiting agents, is
responsible for platelet immunological specificity and mediates platelet-platelet
and platelet-surface interactions. It is composed of three morphological domains:
the exterior coat ("glycocolyx"), the unit membrane, and the submembrane region.
The surface glycoproteins contain sialic acid molecules contributing to a large
negative surface charge which prevents, by electrostatic repulsion, platelets from
sticking to each other and to normal intact endothelium (Gorog et al, 1982). The
unit membrane consists mainly of a phospholipid bilayer and plays an important
role in accelerating blood coagulation. Other important components of the platelet
unit membrane include the membrane endoenzymes particularly the enzymes
involved in membrane transport and cyclic AMP (cAMP) metabolism. The
submembrane region contains a system of filamentous elements and may be
functionally involved in maintaining the platelet discoid shape, pseudopod
formation and clot retraction.
2.2.2 Sol-gel zone
The sol-gel zone comprises the viscous matrix inside the platelet and is composed
of three different fibre systems: submembrane filaments, microtubules and
microfilaments. This zone is also functionally involved in maintaining platelet
shape.
2.2.3 Organelle zone
Several different types of organelle can be detected in the cytoplasm of platelets.
They have a random distribution in non-activated platelets but are centralised
upon activation. The electron dense bodies are intensively opaque and contain a
non-metabolic ("storage") pool of calcium, 5HT, adenosine- 5'-diphosphate and
triphosphate (ADP and ATP), all of which are secreted during the release reaction.
The non-dense granules are the most numerous platelet organelles. Cell
fractionation techniques and cytochemical studies have revealed that they can be
subdivided into alpha-granules, lysosomes and peroxisomes (Bentfeld-Barker and
Bainton, 1982). The alpha-granules are storage sites containing a number of
proteins, including platelet-specific 8-thromboglobulin (BTG) and platelet factor
4 (PF4). These are both tetramers of basic proteins and the plasma levels are
thought to reflect in vivo platelet activation (Ludlam et al, 1975; Kaplan and
Owen, 1981). Lysosomes contain several acid hydrolases and are released into the
external milieu by high concentrations of aggregating agents. Their role may be in
the ultimate disposal of platelet debris during the process of wound healing
following vessel trauma.
2.2.4 Membrane systems
The open canalicular system provides an anastomising network spreading
throughout the cytoplasm giving a greatly enlarged platelet surface area and
making plasma-borne substances much more accessible to the inner part of
platelets. Externalisation of the internalised platelet membranes appears to take
place during platelet shape change (Frojmovic and Milton, 1982), possibly
resulting in the exposure of functional sites. The dense tubular system is derived
from the smooth endoplasmic reticulum and constitutes a continuous network of
narrow canaliculi. It is the major site for calcium which can be mobilised to
regulate contractile events. In addition, prostaglandin metabolism also appears to
be localised in the dense tubular system.
2.3 Aggregation pathways
A process of activation can be inferred to be a pre- requisite for platelet adhesion
and aggregation, from the non-reactivity of normal circulating platelets. It is
probable that no single agent is responsible for the initiation of platelet
aggregation "in vivo". The initiation and perhaps growth of thrombin from platelet
aggregation is influenced by products of the arachidonic acid pathway (Figure 2.1).
Thromboxane (TX)A2 is a metabolite of arachidonic acid and is synthesised within,
and released from the platelet. It is a potent stimulator of platelet aggregation and
constrictor of blood vessels (Hamburg et al, 1975; Moncada and Vane, 1978).
Prostacyclin (PGI2), another arachidonic acid metabolite is produced by
endothelial cells and has opposing actions to TXA2, whereby, it inhibits aggregation
and dilates blood vessels. A balance locally between PGI2 and TXA2 may therefore
prevent thrombosis and haemostatic plug formation (Moncado and Vane, 1978;
Maclntyre et al, 1978). Futhermore it has been suggested that an imbalance in the
PGI2-TXA2 system may contribute to certain pathological conditions including
arterial thrombosis (Lagarde and Dechavanne, 1977), and thrombocytopenic
purpura (Remuzzi et al, 1980). Prostacyclin synthetase, the enzyme which
converts prostaglandin endoperoxides (PGG2 and PGH2) to PGI2 is most highly
concentrated in the intimal surface of the blood vessel, and its concentration
progressively decreases towards the adventitial surface (Moncada et al, 1977;
Moncada and Vane, 1978). Damaged endothelium may have a reduced capacity for
PGI2 production, thus allowing platelet deposition to occur more readily. A fall in
PGI2 production at the site of the damaged vessel may be a contributory factor to
the initiation of thrombus formation.
2.3.1 Primary aggregation
Primary aggregation is a reversible process and results from the direct effect of
agonists at the platelet surface, and it is not effected by inhibitors of the cyclo-
oxygenase pathway. Secondary aggregation occurs as a consequence of the
endogenous synthesis of TXA2 and/or the release reaction. If the stimulus to
produce primary aggregation is not sufficient to induce thromboxane synthesis or
the release reaction, aggregation spontaneously reverses and the platelets retain
their discoid shape (Mustard et al, 1975). Primary aggregation also reflects the
exposure of fibrinogen receptors on the platelet surface, and the interaction with
fibrinogen subsequently enhances cell-cell contact (Mustard et al,1975). This
response requires a lower cytosolic calcium concentration than that necessary to
induce secondary wave aggregation and may involve a pool of bound calcium ions
(Charo et al, 1976; Le Breton and Dinnerstein, 1977). It has also been suggested
that extracellular calcium ions are essential for the primary response since in the
presence of the chelating agent EDTA, primary aggregation is suppressed. In the
presence of physiological calcium concentrations, ADP induces a readily reversible
platelet aggregatory response. However, in a low calcium concentration medium
such as citrated plasma, high concentrations of ADP (1 -2jj_M) induces two phases
of aggregation in human platelets; the second phase is associated with activation of
the arachidonic acid pathway and the release reaction (Mustard et al, 1975).
Human platelets prepared with other anticoagulants such as hirudin and exposed to
physiological calcium concentration only demonstrate primary aggregation waves
(Kinlough-Rathbone et al, 1983).
2.3.2 Secondary aggregation
Although primary aggregation is of considerable pharmacological interest, it may
be an artifact of agonist-induced platelet aggregation in vitro (Armstrong et al,
1983; Kinlough-Rathbone et al, 1983). However, as indicated already, secondary
aggregation occurs as a consequence of the endogenous TXA2 and/or the release
reaction synthesis, and during this reaction the contents of platelet storage vesicles
are released from platelets. Agents that can induce secondary wave aggregation
include thrombin, collagen, PAF and TXA2. They do so through one or both of the
following:
A) by activation of the phospholipase enzymes which cleave arachidonic acid
from membrane phospholipids. Arachidonic acid is then converted to the
prostaglandin endoperoxides (PGG2 and PGH2) and TXA2















The biosynthesis of prostaglandins and thromboxanes from arachidonic
acid
Movement of calcium across platelet membranes appears to be important as the
release reaction can be induced by calcium ionophores (Feinman and Detwiler,
1974) and inhibited by calcium antagonists (Charo et al, 1976). Calcium
movement into the cytoplasm probably exerts an effect on the platelet
microtubules which move towards the centre of the cell in a contractile wave
(White et al, 1972). In addition, activation of the calcium-dependent platelet
actin-myosin complex is also thought to be involved (Haslam and Lynham, 1977;
Daniel et al, 1981. The actin-myosin complex has also been postulated to be
involved in the vesicular fusion of dense bodies with the plasma membrane,
whereby an opening is formed through which the contents are expelled (Daniel et
al, 1981). Protein phosphorylation reaches a maximum before completion of
secondary aggregation and is followed by slow dephosphorylation (Feinstein et al,
1983). No increase in phosphorylation is observed when aggregation without
secretion occurs, and it therefore seems likely that phosphorylation is a pre¬
requisite to the initiation of secretion.
The formation of endogenous TXA2 during secondary wave aggregation occurs due
to activation of phospholipase A2 which induces arachidonic acid release from
membrane phospholipids (Hamburg et al, 1975). The role of endogenous TXA2
was primarily elucidated as a result of studies on the mode of action of non¬
steroidal anti-inflammatory drugs (NSAID) such as aspirin and indomethacin,
which inhibit prostaglandin synthetase (cyclo-oxygenase) enzyme (Vane, 1971;
Moncada and Vane, 1978).
ADP, 5HT and TXA2 potentiate aggregation by either recruiting other platelets, or
in the case of TXA2, trigger further release and it is these events which induce the
second phase of aggregation. In addition, ADP.5HT and TXA2 may act
synergistically with weak aggregating agents such as adrenaline (Kinlough-
Rathbone et al, 1977).
2.3.3 Miscellaneous pathways
A third pathway of aggregation which is independent of both TXA2 and ADP has also
been postulated. In the presence of NSAIDs or ADP removing enzymes (creatinine
phosphate or creatinine and collagen phosphokinase; CP/CPK) thrombin induced
aggregation is only partially inhibited, indicating the involvement of another
mechanism (Kinlough-Rathbone et al, 1977; Cazenave et al, 1979). It has been
suggested that a phospholipid, 1-0-alkyl-2-acetyl-glyceryl-3-
phosphorylcholine (Platelet Activating Factor,PAF) may be the mediator of this
third pathway (Vergaftig et al, 1981). It has been demonstrated that as a
consequence of calcium ionophore stimulation, radioactive acetate incorporated in
platelet membrane phospholipids is subsequently present in PAF. This would
suggest that PAF may play a role as an intracellular mediator of aggregation (Chap
et al, 1981). Furthermore, platelets desensitized to PAF lose their ability to
respond to thrombin. However evidence has been put forward, against PAF as
mediator of the third pathway of aggregation. It has been demonstrated that the
NSAID, acetylsalicylic acid together with CP/CPK completely inhibit PAF-induced
aggregation and secretion (Kloprogge et al, 1983). In addition, both
desensitisation to PAF (Hallam et al, 1984), and congenital absence of PAF
synthesis does not significantly reduce responsive to thrombin or collagen.
Therefore PAF possibly plays only a minor role, if any at all, in platelet activation
induced via a third pathway.
In addition to the three mechanisms described above which require the presence of
agonists, platelets can also aggregate as a result of close cell-cell contact, whereby
activation of the arachidonic acid pathway with the subsequent formation of TXA2
can trigger the release reaction and promote secondary aggregation. This type of
aggregation is blocked by NSAIDs, and the release reaction is secondary to close
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platelet contact and aggregation (Massini and Zuscher, 1974).
2.3.4 Platelet receptors
Irrespective of the precise mechanism underlying the platelet response, whether
it is shape change, primary or secondary wave aggregation, activation of platelets
is initiated by agonist interaction at the surface membrane usually at discrete
receptor sites. Surface receptors have been identified for ADP (Nachman and
Ferris, 1974), thrombin (Detwiler and Feinman, 1973; Tollefsen and
Majerus,1976), adrenaline (Bydgeman and Johnsen, 1969), 5HT and certain
prostaglandins and TXA2 (Le Breton et al, 1979; Nicolaou et al, 1979). In
addition to their action at discrete receptor sites, 5HT and adrenaline, can be
actively taken up into platelets, a phenomenon not associated with aggregation.
Most of the compounds mentioned above induce only aggregation while metabolites
of arachidonic acid can either induce or inhibit aggregation. The prostaglandin
endoperoxides, PGG2/PGH2 and TXA2 fall into the former category, acting at a
"TXA2/endoperoxide receptor". There is controversy as to the true biological
activities of the endoperoxides. For example, it has been reported that thromboxane
synthetase inhibitors virtually abolish arachidonic acid aggregatory activity
(Fitzpatrick and Gorman, 1977), and that the concentrations of endoperoxides in
platelets following arachidonic acid induced aggregation are 100 times lower than
would be required for aggregation. In contrast, it has been demonstrated that the
addition of exogenous PGG2 to platelets "in vitro" induces very rapid aggregation
and release (Claesson and Malsten, 1977). Exogenous PGH2 is degraded in
platelet-rich-plasma predominately to PGD2 and PGE2 with less than 1%
conversion to TXA2 (Oelz et al, 1977). Therefore direct action of PGG2 or PGH2
may be masked by their rapid transformation to PGD2 which is a potent inhibitor
of aggregation (Oelz et al, 1977). This may explain why low levels of
endoperoxides are detected in some studies and why the thromboxane synthetase
inhibitor, Dazoxiben, may block aggregation (Heptinstall and Fox, 1983). In
addition, other workers have suggested that arachidonic acid conversion to TXA2 is
not essential for aggregation (Needleman et al, 1976) supporting the concept that
endoperoxides themselves are capable of inducing aggregation.
However, it is generally assumed that the endoperoxides and TXA2 act on a common
receptor; the greater potency of TXA2 has lead to the designation of "thromboxane
receptor". From a chemical viewpoint the majority of the TXA2 mimetics studied
are in fact endoperoxide-like in structure (Corey et al, 1977; Bundy, 1975).
Furthermore, receptor antagonists are capable of blocking the aggregatory effects
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of both PGH2 and TXA2 suggesting that these antagonists are acting on a common
receptor (Armstrong et al, 1983; Armstrong et al, 1986).
Platelets also contain receptor systems responsive to prostaglandins E-j, I2 and D2.
Occupation of these receptors leads to an activation of adenylate cyclase with
subsequent inhibition of platelet function due to elevations in cyclic AMP. Two
distinct receptors for PGD2 and PGI2 have been identified (Maclntyre and Gordon,
1977) with PGE-| acting on PGI2 receptors. Recently, PGE-| has been reported to
inhibit platelet aggregation independent of cyclic AMP involvement (Sinha and
Colman, 1985). The precise mechanism underlying this inhibition remains to be
elucidated.
2,4 Second messengers
Essentially, platelet responses are evoked by the interaction of agonists at specific
receptors and it is appreciated that such responses are a sequelae of controlled
intracellular reactions mediated by second messengers. Phospholipase A2, a
membrane bound enzyme is stimulated by many agonists, and activation of this
enzyme releases arachidonic acid and possibly PAF acether from membrane
phospholipids which initiates intracellular platelet mechanisms including cyclic
AMP changes and Ca2+ fluxes.
Platelet activation by thrombin and ADP is coupled with phosphoinositide
turnover, with information of intraplatelet second messengers 1,2-diacylgylcerol
and inisitol 1,4,5-triphosphate (IP3) from hydrolysis of phosphatidylinisitol-
4-5- biphosphate (Vickers et al, 1982; Berridge 1984). Subsequent formation
of arachidonic acid from diacylglycerol, and by the activation of phospholipase A2,
yields proaggregatory prostaglandin metabolites, such as TXA2 (Vickers et al,
1982; Berridge 1984).
IP3 has been postulated to act as an intracellular messenger triggering calcium
fluxes. In human platelets stimulated with the endoperoxide analogues (U44069
and U46619), a rapid formation of diacylglycerol and phosphatidic acid has been
reported (Pollock et al, 1984), a process which was found to be insensitive to
non-steroidal anti-inflammatory drugs.
Thrombin can also induce aggregation through activation of phospholipase C with
resultant formation of IP3, despite the presence of aspirin (Di Minno et al,
1986). However the calcium ionophore (U44069) does not activate phospholipase
C in the presence of aspirin, apyrase or CP/CPK, and it seems likely that
phospholipase C is activated by agonists acting through receptors (Seiss et al,
1984). Alternatively, the calcium ionophore activates phospholipase C indirectly
by stimulating phospholipase A2 (which is sensitive to a Ca2+ fluxes) which
releases arachidonic acid, and it is the prostaglandins and TXA2 which induces
phospholipase C to generate polyphosphoinositides (Seiss and Lapetina, 1988).
Cyclic AMP is a further second messenger, and it is generally accepted that
inhibiting agents depress platelet responsiveness as a consequence of an increase in
the level of cAMP (Haslan et al, 1978). It is generated in platelets by stimulation
of adenylate cyclase and may in part act by increasing intraplatelet calcium
sequestration (Owen et al, 1980). Cyclic AMP also inhibits intracellular release
of calcium and influx from the surrounding media (Feinstein et al, 1983), thus
reducing protein phosphorylation due to a restriction in the amount of cytoplasmic
calcium available to these enzymes (Kawahara et al, 1980). Futhermore the
lowering of cytoplasmic calcium by cyclic AMP stimulators closely corresponds to
its ability to reverse thrombin induced aggregation, protein phosphorylation and
cytoskeleton assembly (Feinstein et al, 1983). It has been postulated that a
cAMP dependent protein-kinase is involved in calcium ion reuptake, and the
phosphorylation of proteins which are involved in the active pumping of calcium
ions from the cytoplasm to intracellular stores. Studies have also suggested that
increases in cAMP may depress phospholipase C activity in intact platelets and in
this situation cAMP would be modulating the response of calcium indirectly by
exerting control at the level of diacylglycerol (Rittenhouse-Simmons, 1979). In
addition to stimulating active sequestration of calcium, and the inhibition of the
phospholipase C enzyme, several groups have reported that an elevation in cAMP
inhibits both arachadonate liberation from phospholipids (Gerrard et al, 1977;
Lapetina et al, 1977) and possibly the cyclo-oxygenase enzyme (Malmsten et al,
1976): both of these enzymatic processes being calcium dependent.
The ability of cAMP therefore to lower cytosolic calcium, highlights an
important role for cAMP, both as a modulator of the initiation of platelet activation
and in reversal of the activation process following stimulation.
It is clear from this chapter that platelets are complex entities. They function as a
result of the interactions of many biochemical processes occurring at the surface
membrane and the intracellular organelles, and only through pharmacological
manipulations have many of the underlying mechanisms been elucidated.
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PART A
3.1 Introduction
The major function of neutrophil granulocytes is to prevent or retard the intrusion
of infectious agents and other foreign material into the host environment. This is
accompanied by phagocytosis and digestion of the material. Neutrophils also
release various substances into their environment and thus also have a secretory
function.
Neutrophil production in normal adult man appears to take place only in the bone
marrow. The life cycle of the neutrophil can be divided conveniently into bone
marrow, blood and tissue phases. It is assumed that cells move through the system
in a more or less orderly manner as if in a pipeline: this view is supported by the
progressive movement of isotopic tracers (Maloney and Patt, 1958) and
azurophilic granules (Wetzel, 1970) through the system.
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3.2 Neutrophil granules
There are two granule types in neutrophils; one comprises about one-third of all
neutrophil granules, serves primarily an intracellular role, and has the
characteristics of lysosymes. The other granules, which are more abundant, are
readily accessible to extracellular release, and in many respects are like granules
secreted by secretary organs. The maturation characteristics of neutrophils
clarifies the two types of granules. Neutrophil development occurs in two phases:
the mitotic and post-mitotic phase both last around a week. The first granules
appear in the promyelocytic stage. They are packaged and released from the inner
concave surface of the Golgi apparatus, and stain azurophilic in the bone marrow.
They appear first, and are therefore also called the "primary" granules. Later in
maturation these granules stop being synthesised and are distributed uniformly in
daughter cells so that in mature neutrophils there are relatively few primary
granules. By this stage, a second granule predominates which is formed and
released from the outer convex surface of the Golgi apparatus. Since these granules
occur second in granule maturation, they are called "secondary" granules and
because they also have unique qualities, they are also called "specific" granules.
The specific granules are particularly accessible for fusion with the plasma
Table 3.1































'Secondary granule collagenase is released as a latent enzyme
membrane (Bainton, 1977) with release of their contents to the extracellular
environment. These granules defer a secretory function to neutrophils which,
unlike more classical organs, are dispersed throughout the body.
3.3 Human neutrophil elastase
Human neutrophil elastase is a serine proteinase which occurs in neutrophils and
myeloid precursors, and is largely concentrated in the azurophilic granules ' of
granulocytes (Janoff, 1985). It is a single-chain polypeptide with a strongly
basic isoelectric pH, and is discharged into plasma when the cell encounters objects
to be phagocytosed or undergoes death. Turnover of connective tissue
macromolecules by elastase secreted by histiocytes (tissue macrophages), smooth
muscle cells, and fibroblasts appears to reflect a physiological process. However,
hydrolysis of matrix molecules by neutrophil elastase probably reflects a
pathological process (Janoff, 1985). In the latter situation, a wide variety of
structurally important proteins and glycoproteins can be attacked by the
neutrophil elastase; elastin, being an obvious target (Janoff and Scherer, 1968).
Neutrophil elastase can also cleave core proteins off proteoglycan molecules in the
connective tissue ground substance (Kaiser et al, 1976). This can interfere with
water entrapment by proteoglycan complexes, and in joint cartilage, spoil
mechanical functions such as resistance to compressive forces. Other important
structural targets include types (iii) and (iv) collagen; type (iii) collagen being a
major supporting component of blood vessels, lung connective tissue and gut. Type
(iv) collagen is important maintaining the structural integrity of epithelial and
endothelial basement membranes. Fibronectin, a major cell-adhesion molecule, is
another structural macromolecule susceptible to degradation (McDonald and Kelly,
1980). Although it was once thought that the connective tissue matrix acted only
as an extracellular scaffold, it has been clearly shown to serve as an interactive
substratum that regulates the shape, migration, growth, and differentiation of
cells. In addition, it also has an important role in the orderly repair of damaged
tissues (Vracko, 1974). Thus, if neutrophils mediate the dissolution of
extracellular matrix, then it is probable that this leads to functional and
structural damage.
In addition to connective tissue architectural components, many plasma proteins
can be hydrolyzed by neutrophil elastase. Potential substrates include
immunoglobulins, clotting factors (including fibrinogen) and complement proteins
(Janoff, 1985). Inactivation or activation of plasma cascades may have important
local and systemic consequences (Plow, 1982). Formed blood elements can also be
effected by the enzyme with both lymphocyte activation and platelet aggregation
having been described (Havemann and Gramse, 1984).
Neutrophil elastase activity is normally restricted to the phagocytic vacoule and
the immediate environment of the cell, and usually involves the presence of
circulating and locally produced elastase inhibitors. Circulating inhibitors include
alpha-1 -proteinase inhibitor (formerly known as alpha-1-antitrypsin) and
alpha-2-macroglobulin. Locally produced regulators of importance are
"antileukoprotease" (Fritz et al, 1978) which are low molecular weight, acid-
stable inhibitors present in bronchial, cervical and seminal plasma. Alpha-1-
proteinase inhibitor appears to be the most important regulator of neutrophil
elastase activity, and functions by complexing with elastase after being cleaved
(Brower and Harpel, 1983). It is a glycoprotein synthesised in the liver, has a
molecular weight of 52 kd, and individuals lacking normal levels in their
circulation and bronchoalveolar fluids are at risk of developing chronic
obstructive airways disease (Larrell and Erikson, 1963).
In vivo, the calculated half-life of active elastase is only about 0.6 msec; by 3
msec all activity should be inhibited (Travis and Salvesen, 1983). Given the
effectiveness and multiplicity of the inhibitors that comprise the anti-elastase
shield, it might seem reasonable to assume that neutrophil elastase would not have
the opportunity to mediate extracellular tissue damage. However, there is
considerable evidence that neutrophils not only circumvent the entire anti-
proteinase shield, but also are able to use their discharged elastase to attack and
destroy host tissues. For example, it has been demonstrated that isolates of
purulent fluids recovered from sites of inflammation contain free neutrophil
enzymes capable of degrading a variety of native and denatured proteins at neutral
pH (Opie 1922; Weiss and Regiani, 1 984). Alpha-1-proteinase inhibitor
contains methionine at its reactive centre (position 358) which is sensitive to
oxidation by either chemical reagents or triggered neutrophils. It seems likely
that this causes a significant decrease (approximately 2000 fold) in the rate of
association between neutrophil elastase and the modified anti-1-proteinase




Neutrophils are motile, and are therefore free to migrate into sites of
inflammation. Once in the area of inflammation they come into contact with foreign
material, engulf it, and subject it to the bactericidal and digestive enzymes that
they contain. Endocytosis is the process by which material is taken into a cell
enclosed within pieces of plasma membrane without the material at any time
occurring free in the cytoplasm of the cell (Cohn and Hirsch,1960; de Duve and
Watliaux, 1966). Endocytosis is further divided into pinocytosis (drinking by
cells) and phagocytosis (eating by cells). Phagocytosis can usually be seen by light
microscopy, whereas pinocytosis cannot because it involves ingestion of much
smaller particles. Both processes involve invagination of the cell membrane and
the formation of vesicles or vacouies (phagasomes). Although neutrophils ingest
foreign material, they rarely ingest autologous cells (Vaughn, 1965)
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3.5 Phagocytosis and bacterial killing
The ingestion of particles by phagocytic cells requires the expenditure of energy
(Karnovsky, 1968) and is accompanied or immediately followed by a variety of
complex biochemical events. Although neutrophils contain a cytochrome system
(Cline, 1965) and may use both aerobic and anaerobic mechanisms to produce
energy, they utilise anaerobic glycolysis to support phagocytosis (Shara and
Karnovsky,1959). During ingestion the particle is surrounded by pseudopodia and
the cell membrane invaginates to enclose and internalise it (Goodman and Moore,
1956). This phase is rapidly followed by a fusion of lysosome granules into the
phagocytic vacoule (Cohn and Hirsch, 1960). In neutrophils, the content of
specific granules are released into the phagasomes first (within 30 seconds), and
the contents of primary granules are found in the phagasome later (1-3 minutes).
After fusion, bacteria are usually killed quickly and the phagocytosed material is
digested. Two principally different mechanisms appear to be responsible for the
bacterial killing by neutrophils. One is dependent upon the uptake of oxygen and
the formation of toxic oxygen species; the other is dependent on the action of pre¬
formed bactericidal granule proteins such as cathepsin G, lactoferrin, lysozyme,
myeloperoxidase and permeability-increasing protein (Epstein, 1989). In
addition, elastase, although not bactericidal by itself, may act by potentiating the
bactericidal properties of other components (Havemann and Gramse, 1984).
The "respiratory burst" that occurs during bactericidal killing refers to a series
of metabolic events that take place when neutrophils are appropriately stimulated,
namely, an increase in oxygen consumption, the production of superoxide, activated
oxygen species, and increase in glucose oxidation via the hexose-monophosphate
shunt (Barbior, 1978). These events depend on the activity of an oxidase which
catalyzes the one electron reduction of oxygen to superoxide, using an electron
donor such as nicotinamide adenine dinucleotide phosphate (NADPH) (Barbior,
1978). In the presence of iron salts, particularly neutrophil lactoferrin,
hydrogen peroxide can be converted to hydroxyl radicals (Ambruso and Johnston,
1981). Neutrophil myeloperoxidase, which is present in high concentration in the
azurophilic granules of neutrophils is released into the phagasome during granule-
phagasome fusion (Klebanoff, 1970). Myeloperoxidase, in the presence of
hydrogen peroxide and a halide, is responsible for further catalyzing the formation
of additional oxidants such as hypochlorous acid and free chlorine (Figure 3.1).




MYELOPEROXIDASE H2O2 + ci- HOC1
Proposed mechanism for neutrophil-derived free radicals and toxid oxygen
metabolites. Membrane-associated NADPH oxidase reduces molecular oxygen
to form superoxide anion (0^), singlet oxygen (102) and hydroxyl radical
HO*. The granule-associated myeloperoxidase catalyses the conversion of
hydrogen peroxide (^0 ) ^oxic metabolite hypocholorous acid (H0C1).
mycoplasma; this system is also toxic to other cells including tumour cells.
As has already been indicated, human neutrophil polymorphonuclear leucocytes
provide an effective defence against bacteria and fungal infection. However, they
may also have an important role in the pathogenesis of tissue damage in certain
non-infective diseases (Malech and Gallin, 1987). Mild to moderate abnormalities
of neutrophil function have been reported in many acquired and congenital diseases
(White and Gallin, 1986; Rotrosen and Gallin, 1987) and in most of the disorders,
the biochemical and morphological basis are still unclear. Neutrophil elastase and
free radical activity have been implicated in the development of myocardial,
ischaemia and infarction (Werns et al, 1986; Simpson et al, 1987). In addition,
there is synergism between neutrophil elastase and oxidizing systems; activated
oxygen species and activated halides can not only damage tissue themselves, but can
also inactivate alpha-1 -proteinase inhibitor (Janoff, 1985). Elastase-mediated
injury to airways has been implicated as a pathogenic factor in cystic fibrosis
(Jackson et al, 1984; Suter et al, 1984); increased levels of active neutrophil
elastase have been reported in bronchoalveolar washings from patients acutely ill
with respiratory distress syndrome (Lee et al, 1981; McGuire et al, 1982; Till et
al, 1982), and as has already been discussed, neutrophil, monocyte and
macrophage elastases have also been implicated in the development of emphysema
(Janoff, 1985).
3.6 Plasma free radical activity
It seems likely that free radical activity in plasma is derived from a number of
sources. Neutrophil NADPH oxidase and myeloperoxidase produce toxic oxygen
metabolites, and are possibly the major source. In addition at least three other
sites may contribute. Vascular endothelium, particularly during periods of
ischaemia and reperfusion, is a further source (Werns et al, 1986; Simpson et al,
1987). The cytosolic enzyme xanthine oxidase is normally present in a
dehydrogenase form. During ischaemia, the dehydrogenase form is converted to the
true oxidase form, which uses oxygen, instead of nicotinamide adenine, as an
electron acceptor. On reperfusion of ischaemia tissue, the delivered oxygen can
be reduced by this system, producing superoxide and hydrogen peroxide (McCord,
1985; Chambers et al, 1985). (Figure 3.2). Free radicals are also synthesised
during arachidonic metabolism (Yamato, 1983; Kontos, 1987); activated
phospholipids release arachidonic acid which accelerates synthesis of free radical













Hypoxanthine : *" O2 + H2O2 + Urate
02
Reoxygenation
Proposed mechanism for free radical injury induced by anoxia-reoxygenation
(ATP = adenosine_triphosphate; ADP = adenosine diphosphate; AMP = adenosine
monophosphate; 0^ = superoxide radical; = hydrogen peroxide).
radicals may be derived from the hepatic microsomal system, and indeed
hepatocytes from ketotic rats produce increased lipid peroxidation which can be
suppressed in vitro by insulin (Kosugi et al, 1984).
As discussed elsewhere, unless free radicals are rapidly eliminated, they are
capable of producing cellular and tissue damage (Fridovich, 1978). The levels of
the activated oxygen species are controlled by various cellular defence
mechanisms consisting of enzymatic (superoxide dismutase, catalase and
glutathione peroxidase) and non-enzymatic (glutathione and vitamin E) scavenger
components (Simmons, 1984; Halliwell and Gutteridge, 1984). There is
increasing evidence that, in certain pathological states, along with increased free
radical activity, the ineffective scavenging of such activated oxygen species may
play a role in the development of tissue injury (Halliwell and Gutteridge, 1984;
Dormandy, 1983).
Free radicals have a lifespan of microseconds and their concentration at any site at
any moment is miniscule. Therefore the evidence for their existence is mostly
indirect. Superoxide dismutase, which uses the free radical anion superoxide as a
substrate (McCord and Fridovich, 1977), has been the chief enzyme and
scavenging system investigated. The reduced concentration of superoxide dismutase
and other scavenging enzyme systems, is usually interpreted as reflecting
increased free radical activity (McCord and Fridovich, 1977; Dormandy, 1983).
Recently, as discussed in Chapter 10, it has been demonstrated that the free
radical mediated oxidation product of linoleic acid, PL-9,11-LA', is a good marker
for free radical activity (Cawood et al, 1983; Iversen et al, 1984).
©ri^PTMB 4
PLATELET DENSITY ANALYSIS





PLATELET DENSITY ANALYSIS AND INTRAPLATELET GRANULE CONTENT




4.3.1 Platelet density analysis
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It is recognised that circulating platelets are heterogeneous with respect to
function, volume and density; however the exact mechanism by which this
heterogeneity is created remains controversial. It may arise in the bone marrow
during the production of platelets by megakaryocytes (Thomson et al, 1983) or,
alternatively, within the circulation after liberation from the marrow. The latter
possibility has aroused much controversy; some studies report an increase in
density as platelets age in the circulation (Mezzano et ai, 1381; Boneu et al,
1982) whereas the more traditional view is that they become less dense during
their lifespan (Corash and Shafer, 1982, Rand et al, 1983). Watson and Ludlam
(1986) investigated platelet-density and survival in normal and post-
splenectomized subjects, and concluded that high density platelets were
preferentially retained in the spleen and have a more prolonged survival than those
of lower density.
Platelets contain several classes of secretory granules, including lysosomes,
electron-dense granules (containing ADP, serotonin (5-HT), and Ca^ + ) and
alpha-granules (containing (3 thromboglobulin (6TG), fibrinogen, platelet factor
4, factor V (proaccelerin), and factor VIII), and during aggregation these are
released into the surrounding plasma. Cieslar et al (1979) demonstrated that
platelet de-granulation, induced by thrombin, was accompanied by a decrease in
platelet density, and it has been proposed that the alpha-granule content is the
major determinant of platelet density in vivo (Vicic and Weiss, 1983; van Oost et
al, 1984). After a study of the relationship between platelet-density distribution
and granule-marker levels in acquired storage-pool disease, Boneu et al (1983)
suggested that platelet-density analysis might be a useful screening test to detect
activated platelets in the circulation. In this study, the density profiles of platelets
from insulin-dependent patients with differing prevailing metabolic control have
been investigated, and related to their intraplatelet granule content.
4JL Subjects
Thirty-two insulin-dependent diabetic patients (18 males, 14 females) aged 29.4
± 3.6 years (mean ± SD), mean duration of diabetes 11.0 ± 2.9 years and 10
comparable non-diabetic controls (6 males, 4 females) aged 29.5 ± 4.1 years
were studied. The diabetic patients were divided into three groups according to
Table 4.1
Clinical details of diabetic patients and control subjects
























2 8 7±4 7 1 0.9±3.6
300±54 1 2.1 ±4.1
2 79±30 1 1 . 7±2.9
Values expressed as mean ± SD
their prevailing glycaemic control (group A, HbA-| < 9%; group B, HbA-| =10-
13%; group C, HbA-) > 13% ). None were taking medication other than insulin.
All had normal renal function (plasma creatinine <120 p.mol/1, urine Albustix
negative), were normotensive (BP <140/90) and had easily palpable peripheral
pulses. Retinopathy was assessed after mydriasis, and nine of the patients had
background retinopathy (ranging from a few microaneurysms to exudative
changes) and they were distributed through the three groups (Table 4.1).
4.3 Methods
4.3.1 Platelet density analysis
Working solutions of Percoll (Pharmacia, Piscataway, NJ) were prepared with
phosphate-buffered saline (pH 7.4) containing 0.01 M EDTA as dilutent. Percoll
consists of colloidal silica particles of 15-30nm diameter which have been coated
with polyvinylpyrrolodone. Ten millilitres of each solution were used to prepare
continuous linear gradients covering the range 1.04- 1.12g/ml. The gradients
were calibrated with coloured marker beads (Pharmacia). Blood samples (5ml)
were collected into EDTA (final concentration 0.15%) and prostaglandin (PGE-|)
was then added to each sample (final concentration 0.2 p.g/ml). The blood was
diluted 1:1 (vol/vol) with 0.9% saline before carefully layering 2.5ml onto a
Percoll gradient. Gradients were spun for 60 minutes at 2000g (at room
temperature) and then fractionated by upward displacement of the gradient with
stock Percoll. Platelet counts were performed with a Coulter Plus Z3 (Coulter
Electronics Ltd, Luton, UK). The average recovery of platelets from gradients was
76%.
4.3.2 Measurement of intraplatelet nucleotides
Platelet nucleotides were extracted from platelet-rich plasma (PRP) with 1 vol of
a solution of trichloracetic acid (10% wt/vol) and EDTA (4mM) for 10min at 4°C.
Nucleotides were then assayed by the method of Holmsen et al (1972) with the kit
and reagents supplied by LKB (South Croyden, UK).
4.3.3 Measurement of intraplatelet B-thromboglobulin
6-thromboglobulin was assayed by radioimmunoassay with the method of Bolton et
al (1976). The amount of BTG present in platelets was estimated after lysis of
EDTA-PRP (with a known platelet count) with Triton X-100.
4.3.4 Glycosylated haemoglobin
The glycosylated haemoglobulin (HbA-|) was carried out by electrophoresis with
commercially available agar (Corning Medical, Halstead, UK) as described by Read
et al (1980).
4.3.5 Statistical analysis
Statistical analysis of the density profiles was by Spearman rank-correlation
analysis.
4.4 Results
Under the conditions used in the study, normal platelets layered onto Percoll
formed a band from 1.0625g/ml to 1.0925g/ml with a mean density of
Figure 4.1
PERCOLL OEKSIIY. CJRL4
Platelet-density profiles of normal (solid curves) and diabetic
(dashed curves) groups. Results expressed as mean + SD.
A, HbA1 $ 9%; B, HbA1 = 10-13%; C, HbA1> 13%
Table 4.2






























Values are expressed as mean ± SD
1.0775g/ml; the distribution of platelets on gradients was bell shaped. In
diabetic patients with an HbA-j <9%, the platelet density profile was
superimposable with that of normal subjects. However, in the two diabetic groups
with a HbA-| >10%, there was a significant increase in the proportion of low
density platelets observed on Percoll (p< 0.0002) and the mean platelet density
was reduced to 1.0750g/ml (10 < HbA-| < 13%) and 1.0700g/ml (HbA-| >13%)
(Figure 4.1). Microscopic examination of gradient fractions did not show any
evidence that platelet aggregation during centrifugation.
There was no significant difference in the intraplatelet nucleotides (ADP and ATP)
and 8-TG contents of the diabetic patients and control subjects (Table 4.2).
4,5 Discussion
When a suspension of particles is centrifuged, the sedimentation rate of the
particles is proportional to the force applied. The physical properties of the
solution will also affect the sedimentation rate. At a fixed centrifugal force and
liquid viscosity, the sedimentation rate is proportional to the size of the particle
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and the difference between its density and the density of the surrounding medium.
The equation for the sedimentation of a sphere in a centrifugal field is:
v = d2 (pp - p| ) x g
18/1
where v = sedimentation rate
d = diameter of the particle
Pp = particle density
Pl = liquid density
j\ = viscosity of the medium
g = centrifugal force
From this equation the following relationships can be observed:
(i) sedimentation rate of a particle is proportional to its size
(i i) sedimentation rate is proportional to the difference between the density of the
particle and that of the surrounding medium
(i i i) sedimentation rate is zero when the density of the particle is equal to the
density of the surrounding medium
(iv) sedimentation rate decreases as the viscosity of the medium increases
(v) sedimentation rate increases as the centrifugal force increases
Rate zonal centrifugation and isopycnic centrifugation are the two types of
centrifugation used with Percoll. With rate zonal centrifugation, the size
difference between particles is the parameter that determines separation. As can
be seen from the above equation, large particles move faster through the gradient
than small particles, and the density range is chosen so that the density of the
particles is greater than the density of the medium at all points during the
centrifugation. The run is terminated before the separated zones reach the bottom
of the tube (or their equilibrium positions).
In this study, the isopycnic centrifugation technique was used. With this, the
density range of the gradient medium encompasses all the densities of the sample
particles. Each particle sediments to an equilibrium position in the gradient
where the gradient density is equal to the density of the particle (isopycnic
position). Thus in this type of separation, the particles are separated solely on the
basis of differences in density, irrespective of size.
Previous studies of platelet-density heterogeneity have used various density-
gradient separation media such as Stractan (Mezzano et al, 1981; Boneu et al,
1982), Ludox-PVP (Penington et al, 1976), bovine serum albumin (Charmatz
and Karpatkin, 1974) and sucrose (Booyse et al, 1968). Recently, Percoll has
been introduced as an alternative medium for the preparation of platelet
subpopulations of various densities (Martin et al, 1983), and when used in
continuous gradients it appears to overcome the problems associated with viscous
density-gradient media and discontinuous gradients. With discontinuous gradients,
subpopulations of platelets appear to be trapped at the step interface, and with both
this type of gradient and viscous density-gradient media, the time taken to reach
equilibrium is substantially increased (Martin and Trowbridge, 1982). In this
study, the formation of platelet aggregates during centrifugation was inhibited by
the addition of PGE-j to blood samples and the use of suitably buffered Percoll.
Using density analysis, this study demonstrated an increase in low-density
platelets in the peripheral blood of poorly controlled diabetic patients. However,
there was no correlation between the presence of increased numbers of low-
density platelets and the presence of microangiopathy in the form of retinopathy.
Further investigations revealed normal levels of alpha-granules (6TG) and dense
granule (ADP/ATP) contents in the platelets of these individuals. The increase in
the number of low density platelets may occur as a result of the influence on
platelet density of platelet aging (Thomson et al, 1983; Blajchman et al, 1981;
Watson and Ludlam 1986), the platelet membrane (Rand et al, 1983), or other
intraplatelet protein constituents. Particularly, platelet protein constituents may
undergo non-enzymatic glycosylation (Brownlee et al, 1984), similar to
erythrocyte glycosylation (Agarwal et al, 1985), causing an alteration in platelet
density. Alternatively, it has been demonstrated that the proportion of
megathrombocytes present in the peripheral blood is increased in diabetes mellitus
and in other conditions in which platelet survival is shortened (Garg et al, 1972;
Abrahamson, 1968). The heterogeneity of platelet density may occur as a result of
platelets of various sizes having comparable granule contents.
Also, some external factor may have contributed to the result in this study.
Diabetic platelets have been shown to possess a refractoriness to the inhibitory
action of prostaglandins (Betteridge et al, 1982; Davi et al, 1982). PGE-) is
effective in preventing aggregation of normal platelets on gradients during
centrifugation. The diabetic platelets, however, may not have been as responsive to
PGE-|, and it is possible that a small loss of granule content may have occurred
despite the mild centrifugation conditions. If this were the case, it would suggest
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It is recognised that platelets from diabetic patients show an exaggerated response
to aggregating agents (Colwell et al, 1983). Hyperaggregation has been reported to
be associated with poor glycaemic control (Peterson et al, 1977), increasing age
(Lecrubier et al, 1980), and the presence of micro and macrovascular
complications (Khosla et al, 1979; Colwell et al, 1977). A number of circulating
substances relevant to coagulation, including lipids (Stuart et al, 1980; Jones et
al, 1986), fibrinogen (Cederholm-Williams et al, 1981) and von Willebrand
factor (Lamberton et al, 1984) have also been reported as abnormal in diabetic
patients.
Where a possible mechanism for enhanced platelet aggregation has been
investigated, the most consistent finding has been the increased production of
aggregation-induced thromboxane A2 (TXA2) (Ziboh et al, 1979; Halushka et al,
1981; Silberbauer et al, 1981). TXA2, which is the predominant metabolite of
platelet arachidonic acid, is a powerful platelet aggregator and vasoconstrictor
(Hamburg et al, 1975; Moncada and Vane, 1978). Most studies have employed
arachidonic acid itself or an agent such as collagen, which releases endogenous
platelet arachidonic acid, to demonstrate enhanced platelet aggregation. Since the
production of TXA2 is known to be increased, it cannot be determined from these
studies (Peterson and Gormsen, 1978; Davis et al, 1978) whether improved
receptor coupling or an increase in the number of thromboxane receptors may also
contribute to this increased sensitivity.
The aims of this study were to confirm platelet hyperaggregability to collagen and
to investigate the changes at receptor level in platelets from diabetic patients with
established microangiopathy using an analogue of PGH2, 11,9-epoxymethano PGH2
(11,9-em PGH2), which directly stimulates thromboxane receptors (Di Minno et
al, 1981; Di Minno et al, 1985), plus a competitive thromboxane receptor
antagonist (EP 092) (Jones et al, 1982) (Figure 5.1). Young insulin dependent
diabetic patients who had background and proliferative retinopathy, as well as a
comparable non-diabetic control group were selected in order to investigate the






Structures of thromboxane A^, 11,9-epoxymethano-prostagladin
(thromboxane mimetic) and EP 092 (thromboxane receptor antagonist)
5.2 Subjects
Twenty-four insulin dependent diabetic patients and twelve non-diabetic healthy
volunteers were studied. Classification of retinopathy was based on both
ophthalmoscopic and fluorescein angiographic appearances. Twelve patients had
background retinopathy and twelve had proliferative retinopathy. In the
background retinopathy group, three patients had scattered microaneurysms and
haemorrhages, seven patients had hard exudative changes and two patients had
ischaemic preproliferative changes. The three groups were comparable for age and
sex, and the diabetic groups were matched for duration of diabetes (Table 5.1).
None of the diabetic subjects were taking medication other than insulin, all were
clinically free of nephropathy (plasma creatinine <120 pmol/l, urine Albustix
negative), were normotensive (BP<140/90) and all had easily palpable
peripheral pulses.
Table 5.1
Age, duration of diabetes, plasma glucose, HbA-| and platelet counts in controls and
diabetic retinopathy groups
Group Number Age Duration Plasma HbA1 Platelet
of (years) of diabetes glucose (%) Count
subject (years) (mmol/l) (x 1 09/I)
Control 12(6M,6F) 26.7(1.3) - 4.6(0.3) 7.6(0.3) 274(1 1)
Background
Retinopathy 12(6M,6F) 27.6(0.9) 15.2(1.1) 10.5(1.0) 1 1.8(0.7) 257(16)
Proliferative
Retinopathy 12(6M,6F) 27.0(1.5)* 14.6(1.4)** 1 1 .6( 1 .7)** 1 2.6(0.7)** 245(1 .2)*'
Results expressed as mean (SEM)
NS between the three groups
** NS between the diabetic groups
5.3 Methods
5.3.1 Preparation of platelet suspensions
All manipulations were carried out at room temperature. Blood (100mls) was
collected between 8.00 and 9.00 hours from fasted diabetic patients and control
subjects into plastic centrifuge tubes containing acid-citrate dextrose (1ml for
5ml blood) and centrifuged at 120g for 20 minutes. The platelet-rich plasma
(PRP) was then pre-incubated with [14°C] 5-hydroxytryptamine (final
concentration 1 pg/ml) for 30 minutes. The platelet suspensions were kept under
an atmosphere of 95% 02/5% CO2 which kept the pH constant, and therefore
prevented the fall in sensitivity to thromboxane-like action which occurs with
time (Kerry and Paton, 1984).
5.3.2 Platelet aggregation measurements
Platelet aggregation was measured by the turbidometric method of Born (1962),
using a Bryson Aggregometer (II Upchurch and Co Ltd). The changes in light
transmission of the platelet suspension were recorded on a potentiometric recorder
(Servoscribe Is) The cell block was maintained at 37°C and stirring was achieved













Dose response curves for aggregation induced by collagen and 11,9-em PGH were
determined both in the presence and absence of the cyclooxygenase inhibitor,
Froben (10 pmol/l). This eliminated the endogenous production of TXA2 and
allowed assessment of aggregation in the absence of the secondary aggregation
wave. In addition, the shift in the dose-response curve for aggregation using a
fixed concentration of the competitive TXA2 receptor antagonist EP 092 (0.25
|imol/l) was established. Each aliquot was warmed to 37°C for 2 minutes with
constant stirring (1100 rev/min) prior to the addition of the aggregating agents.
If used, Froben or EP 092 were added at time zero, 2 minutes before the addition of
the aggregating agent.
5.3.3 Measurement of 5-hydroxytryptamine (5-HT) release from platelets
Platelet rich plasma was pre-incubated with radiolabeled 5HT(5-hydroxy-
(side-chain) 2-[14C]-tryptamine) at 37°C for 30 minutes. The [14C]-5HT is
actively taken up by the platelet into the dense granular bodies during this pre¬
incubation period. Following the incubation period, platelet rich plasma was used
in aggregation studies as described. In order to estimate [14C]-5HT release, at the
end of the four minute period, 200 pi samples in duplicate were withdrawn from
the cuvette and added to 0.8ml ice cold EDTA (0.4% w/v in 0.9% saline) in an
Eppendorf tube. The quenched samples were centrifuged immediately at 16000g
(20°C for 30 seconds) in a bench Eppendorf centrifuge. Subsamples (0.5ml) of
the cell free supernatant were then transferred into 10ml of scintillant (PCS-
Amersham-Searle/toluene 2:1) and conventional scintillation counting carried
out. The [14CJ-5HT released was expressed as a percentage of the amount of
[14C]-5HT taken up by the platelets.
5.3.4 Measurement of intraplatelet 3:5 cyclic monophosphate (cAMP)
This assay is based upon competition between unlabelled cAMP and a fixed quantity
of 3h labelled cAMP for binding to a protein which has high specificity and affinity
for cAMP. PGE-j (0.2 pmol/l) was incubated with the platelet suspension (1ml)
for 37°C for 30 seconds. The reaction was quenched by addition of 2ml ethanol and
5 mins later the sample was centrifuged at 2000g. The supernatant was removed
and the pellet suspended in 1ml ethanohwater (2:1) and centrifugation repeated.
The combined supernatants were evaporated to dryness at 55°C under a stream of
nitrogen. The residue was dissolved in 0.5ml assay buffer and centrifuged at
12,000g for 30 seconds to remove insoluble material. Duplicate 50 pi samples
were removed and their cAMP content measured by a protein- binding assay
(Gilman 1970, Armstrong et al, 1985). The extraction procedure gave a mean
recovery of 87 ± 1.4% (16 replicates); the inter-assay coefficient of variation
was 11% while the intra-assay coefficient of variation was 4%.
5.3.5 Radioimmunoassay of thromboxane B2
The underlying principle of radioimmunoassay depends upon competitive binding,
where labelled and unlabelled antigen compete for antibody binding sites. The
distribution of radionucleotide counts in the bound and free states is proportional
to the relative concentration of unlabelled antigen. TXB2 concentrations are
thought to reflect the levels of the active precursor TXA2 present from
biosynthetic transformations of arachidonic acid.
The TXB2 antibody used was obtained commercially from The Pasteur Institute,
France, in freeze dried form, and before use was reconstituted in phosphate buffer
pH 7.5. TXB2 produced in response to exogenous collagen (2 pg/ml) was measured
in duplicate using a standard double antibody technique. Collagen was added to 1ml
PRP and incubated at 37°C for 30 seconds. The reaction was then quenched with
2M HCI and the TXB2 then extracted into ethylacetate (Et Ac). The Et Ac was then
removed after centrifugation at 2000g for 5 minutes and stored at -20°C until
assayed. The intraassay coefficient of variation was 4.6% while the interassay
coefficient of variation was 3.2%.
5.3.6 Measurement of glycosylated haemoglobin (HbA-|)
Glycosylated haemoglobin was estimated using commercially available agar plates
(Corning Medical, Halstead, UK) as described by Read et al (1980), the normal
range being 6 - 8%.
5.3.7 Statistical analysis
Results are expressed as mean ± SEM. Statistical analysis of the dose ratios levels
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was by Kruskal-Wallis one-way analysis of variance by ranks. Comparison
between the groups for the cAMP and TXB2 results were by Students' t-test with
the Bonferonni correction.
5.4 Results
There was no difference in the concentration of collagen EC50, required to give
50% of the maximum aggregation wave between the two diabetic groups and the
control group (Table 5.2). Similarly, the thromboxane receptor antagonist EP
092 shifted all three curves to a similar extent, as shown by the new EC50 values
in the presence of EP 092, and by the dose ratios (DR = EC50 in the presence of EP
O92/EC50 collagen alone). The cyclooxygenase inhibitor Froben produced a more
marked shift of the control aggregation curves than observed with EP 092. Froben
appeared to be slightly less effective in the proliferative retinopathy group, but
this was not statistically significant.
There was, however, a significant difference between the three groups in the
concentration of 11,9-em PGH2 required to induce 50% aggregation response.
Less 11,9-em PGH2 was required for the proliferative retinopathy group
compared with either the control or retinopathy groups (P < 0.005).
Furthermore, EP 092 produced a significantly larger shift in the aggregation
curve in the proliferative retinopathy group as judged by the dose ratio when
compared with the other two groups (P < 0.005). In the presence of Froben no
difference was found in the three groups (Table 5.3).
5-Hydroxytryptamine release in response to both collagen and 11,9-em PGH2
showed no difference between the three groups. (Table 5.4).
There was no difference in the basal level of cAMP found in platelets from the
three groups or in the rise in cAMP induced by PGE-) (Figure 5.2).
There was a significant increase in the platelet TXB2 production following
exposure to collagen in the proliferative retinopathy (P< 0.05) compared with
the background retinopathy and control groups (Figure 5.3).
Figure 5.2
retinopathy retinopathy
Basal platelet cAMP levels and cAMP levels after exposure to
prostaglandin (PGE^) in control and diabetic retinopathy













Percentage increase in platelet thromboxane Bproduction after
exposure to collagen in the control and diabetic retinopathy groups.
Results expressed as mean + SEM. (* p < 0.05).
Table 5.2
Results of aggregation EC50 and dose ratio for collagen in the presence of EP 092
















Control 0.8(0.1) 1 .9(0.3) 2.4(0.3) 8.3(1.9) 9.8(2.0)
Background
Retinopathy
0.74(0.1) 1.8(0.3) 2.7(0.5) 6.6(1.6) 10.8(3.4)
Proliferative 1.1(0.2)
Retinopathy
1.9(0.4) 1.9(0.2) 4.9(0.7) 5.0(0.5)
NS NS NS NS NS
Results expressed as mean (SEM).
Table 5.3
Results of aggregation EC50 and dose ratio for 11,9em-PGH2 in the presence of EP
092 (0.25 pmol/l) and Froben (10 pmol/l).
Group 11,9emPGH2 11,9emPGH2 Dose 11,9emPGH2 Dose
EC50 +EP 092 Ratio + Froben Ratio
(pg/ml) EC50 EC50
(ug/ml) (p.g/ml)
Control 99.4(1 0.0) 1 1 5.3(5.2) 1.7(0.1) 124.7(9.4) 1.3(0.1)
Background 85.4(1 1.5) 1 93.8(28.4) 2.6(0.6) 1 20(1 2.9) 1.5(0.4)
Retinopathy
Proliferative 63.5(6.6) 1 76.0(20.2) 3.2(0.6) 1 00.4(8.0) 1.6(0.1)
Retinopathy
Results expressed as mean (SEM)
*
p < 0.005, significant difference between proliferative retinopathy and
background retinopathy group
Table 5.4
Results of platelet release in control and diabetic retinopathy groups due to collagen (2
p.g/ml) and 11,9 em-PGH2 (250 pg/ml) alone, and in the presence of EP 092 (0.25
pmol/l) and Froben (10 p.mol/1)
Group Collagen Collagen Collagen 11,9emPGH2 11,9emPGH211,9emPGH2
+ EP092 + Froben + EP092 + Froben
Control 58.8(2.2)41.1(3.6)1 9.8(1.1 )34.9(1.0) 30.9(1.4) 32.7(1.3)
Background 51.8(4.5)39.3(3.9)21.6(1.4)30.8(2.9) 26.7(2.9) 29.3(2.3)
Retinopathy
Proliferative 55.3 (5.7)3 0.7 (4.1 )1 8.4(2.4)32.8(2.9) 28.7(3.4) 30.1(1.7)
Retinopathy
Results expressed as % total [14C]-5HT released/[14C]-5HT taken up by platelets at
pre-incubation and given as mean (SEM).
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5.5 Discussion
This study demonstrated that platelets from insulin-dependent diabetic patients
with proliferative retinopathy are more sensitive to 11,9-em PGH2 than platelets
from insulin-dependent diabetic patients with background retinopathy and control
subjects. However unlike previous studies in diabetic patients (Sagel et al, 1975;
Silberbauer et al, 1981; Janka and Demmel, 1981; Jones et al, 1985), increased
platelet sensitivity to collagen was not found, whether sensitivity was measured as
platelet aggregation or 5-hydroxytryptamine release. In non-diabetic subjects
endogenous PGH2 and TXA2 production are the major components of collagen-
induced aggregation (Vergaftig et al, 1981). The aggregation EC50 for collagen
was similar to the two diabetic and control groups, with the reversible
thromboxane antagonist EP 092 producing a similar shift of the aggregation wave
in each group. The cyclooxygenase inhibitor Froben appeared to be slightly less
effective in the proliferative group than in the background retinopathy and control
groups, but this did not achieve statistical significance. The slight decrease in the
efficiency of Froben in this group is consistent with increased thromboxane
production in response to collagen without alteration in the aggregation EC50 level.
From these observations it would appear that the mechanism for collagen induced
88
aggregation is similar in both diabetic patients and control subjects.
Age is an important determinant of platelet function in both non-diabetic and
diabetic patients (Lecrubier et ai, 1980). During recruitment to this study
particular attention was paid to careful age restriction and comparability. This
may account in part for the apparent discrepancy in platelet collagen sensitivity in
diabetic patients in this study compared with other studies (Sagel et al, 1975;
Silberbauer et al, 1981; Janka and Demmel, 1981; Jones et al, 1985).
In contrast, platelets from the diabetic group with proliferative retinopathy both
produce more thromboxane A2 and were more responsive to the thromboxane
mimetic 11, 9-em PGH2. The increase in sensitivity was reduced in the presence
of the cyclooxygenese inhibitor, Froben. In non-diabetic subjects the major
mechanism of the action of the mimetic does not involve activation of the
thromboxane generating system (Hamburg et al, 1975; Moncada and Vane, 1978).
It would appear however, that in diabetic patients with proliferative retinopathy,
that the increased sensitivity is not a direct effect of the 11, 9-em PGH2 on the
receptor. The actual mechanism remains undefined, but is probably not due to the
increased endogenous thromboxane produced during secondary aggregation.
There was no difference between either the basal level of platelet cAMP levels or
increased cAMP level after exposure to PGE-j between the diabetic patients and
control subjects. This is in agreement with the study by Shepherd et al (1983),
investigating PGI2 binding to platelets but in sharp contrast to that of Lagarde et al
(1981), where lower basal levels of cAMP and a diminished response to inhibiting
prostaglandins were reported. The likely explanation is that in our study and that
reported by Shepherd et al (1983) the subjects were young and age-matched,
whereas in the report by Lagarde et al (1981) the ranges of age, duration of
diabetes and vascular complications were very wide.
In conclusion, this study demonstrates that platelets from insulin-dependent
diabetic patients with proliferative retinopathy both have increased thromboxane
production during aggregation and increased sensitivity to a thromboxane mimetic;
these may be factors in the development of proliferative retinopathy.
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Numerous studies have suggested that platelets from diabetic patients are
hypersensitive to a variety of pro- aggregating agents (Jones & Peterson, 1981;
Colwell et al, 1983). As discussed in the previous chapter, the abnormal platelet
aggregatory response is often associated with an increase in platelet TXA2
synthesis (Buktus et al, 1980; Halushka et al, 1981). The concept of increased
platelet TXA2 production in diabetes is also consistent with the finding that the
platelet aggregation response to arachidonic acid in diabetic patients, is less well
inhibited by the TXA2 antagonist, 13-azaprostanic acid (Le Breton et al, 1979;
Mayfield et al, 1985).
Prostacyclin (PGI2), which is produced in the vascular endothelium has both
potent platelet anti-aggregating and vasodilator activity (Moncada and Vane, 1978;
Gryglewski, 1980). However, in vitro studies have suggested that there is a
reduction in endothelial PGI2 production in diabetic patients (Johnson et al, 1979;
Aanderud et al, 1985), although in vivo measurements contradict this finding
(Mourits Anderson et al, 1986). In addition, it is reported that platelets from
diabetic subjects have reduced sensitivity to PGI2 (Schernthaner et al, 1981;
Betteridge et al, 1982; Davi et ai, 1982) further promoting hyperaggregability.
There is some evidence that improved glycaemic control may reverse some aspects
of the hyperaggregability of diabetic platelets (McDonald et al, 1982; Giugliano et
al, 1982; Evans et al, 1982). Therefore, the aims of this study were to
investigate the changes that occur in ADP-induced platelet aggregation, platelet
sensitivity to a stable PGI2 analogue (Iloprost), aggregation induced platelet TXB2
production, platelet cAMP levels and plasma I3TG levels in nine young insulin-
dependent diabetic patients, in which the glycaemic control was significantly
improved in one group (n=5) over a six month period.
6.2 Subjects
Nine moderately well controlled young male insulin- dependent diabetic patients
participated in the study. Five patients ("tight" control group) improved their
glycaemic control with a fall of HbA-j, from 11.9 ± 1.0% to 9.0 ± 0.8% while the
HbA-| in four patients ("usual" control group) did not change significantly.
Ophthalmoscopy following mydriasis revealed that three patients in the "tight"
Table 6.1
Cinical details of "tight" and "usual" control patients
Duration of HbA-|(%)
Group Age (yrs) diabetes (yrs) To T-|
"Tight" control 30.8 8.8 11.9 9.0*
(n = 5) (28.6-32.8) (6.2-1 0.6) (1 0.1 -12.8)
"Usual" control 29.8 8.6 11.4 11.9
(n = 4) (27.9-32.1) (6.3-9.5) (9.6-12.2) (9.4-13.0)
Results are expressed as mean (range)
*
p < 0.05
control group and two patients in the "usual" control group had mild background
retinopathy. All the patients were normotensive (BP <140/90), had clinically
normal renal function (plasma creatinine <120 pmol/l, urine Albustix negative)
and had easily palpable peripheral pulses. None were taking medication other than
insulin. There was no significant difference in the mean plasma glucose or the
mean platelet count at the time of the venesection in either group.
6.3 Methods
6.3.1 Preparation of platelet suspensions
Platelet suspensions were prepared as described in the previous chapter.
6.3.2 Platelet aggregation methods
Platelet aggregation was measured by the method of Born (1962), using a Bryson
Aggregometer (II Upchurch and Co Ltd). Each aliquot of PRP (0.5 mis) and Krebs
Solution (0.3 mis) was warmed to 37°C for 2 minutes prior to the addition of the
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aggregating agent, ADP. The stable prostacyclin analogue (Iloprost, 1.5 x 10~9M)
was added at time 0, 2 minutes prior to the addition of ADP. Dose response curves
were constructed for aggregation induced by ADP alone, and in the presence of
Iloprost.
6.3.3 Radioimmunoassay of thromboxane B2
Collagen (2 pg/ml) induced platelet thromboxane production was measured in
duplicate by radioimmunoassay using a standard double antibody technique.
6.3.4 Measurement of intraplatelet 3:5 cyclic monophosphate
Basal platelet cAMP and the rise in cAMP induced by Iloprost (1.0 x 10~9M)
were measured by a protein binding assay as described in the previous chapter.
6.3.5 Measurement of plasma 6 thromboglobulin levels
Plasma 8 thromboglobulin levels were measured using radioimmunoassay.
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6.3.6 Glycosylated haemoglobin
Glycosylated haemoglobin was estimated using commercially available agar plates,
the normal range being 6-8%.
6.3.7 Statistical analysis
Results are expressed as mean (range) and statistical analysis was performed
using the Wilcoxon rank sum test.
6.4 Results
With improvement of glycaemic control there was no significant change in the
concentration of ADP required to produce 50 percent of the maximum aggregation
wave response (EC50). However, with improved glycaemic control, there was a
significant increase in the responsiveness of the platelets to Iloprost (p < 0.05).
There was no difference in the platelet TXB2 production between the two groups at
the start of the study (To) (p<0.05) (Table 6.1). There was, however, an
increase in collagen-induced platelet thromboxane production with improved
Table 6.2
Platelet aggregation EC50 for ADP, dose ratio for inhibition by lloprost (1.5 x 10"9
M) and platelet cAMP level (pmol cAMP/ml PRP) after exposure to lloprost at To
and T1.
EC50 f°r ADp ADP Dose-ratio Platelet cAMP level
(10-7 M) for inhibition by after exposure to
lloprost lloprost
Groups To Ti To Ti To Ti
"Tight" control 8.0 6.0 1.3 3.3* 1.2 1.2
(A = 5) (5.4-0.4)(3.2-8.3) (1 .1 -1 .9)(2.5-4,2)( 1 .0-1 .4)(0.9-1 .6)
"Usual control 6.0 6.5 2.5 1.9 1.3 1.2
{ A = 4) (4.1-8.6)(4.2-8.8) (1.6 - 2.8)(1.4 - 2.7)(1.0-1.7)( 1 .0 -1.5)












Ratio of platelet thromboxane (TXjB^ production of 6 months (T^)
with platelet TXB^ production at start of study (To) in the usual
control and tight control groups. Results expressed as mean + SEM.











Ratio of plasma B-thromboglobulin (BTG) level at 6 months (T]_) with
plasma BTG level at start of study (To) in the usual and tight control
groups. Results expressed as mean + SEM. (* p < 0.05).
glycaemic control (p <0.05) (Figure 6.1).
between the platelet cAMP levels before or
but, there was a significant reduction in the
improved glycaemic control (p < 0.05).
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There was no significant difference
after exposure to Iloprost (Table 6.2),
plasma (3TG levels after six months of
6.5 Discussion
In the present study, using a multiple injection regime, five out of nine patients
attained improved glycaemic control. These patients underwent thorough dietary
education, and undertook frequent home blood glucose monitoring. However,
despite the significant improvement in the glycosylated haemoglobin over the six
months, normoglycaemia was not obtained. Therefore, the changes that occurred
in platelet function in this study may be different to those that would have occurred
had normoglycaemia been achieved.
It has been recognised that some aspects of the hyperaggregation of diabetic
platelets may be reversed following insulin treatment (McDonald et al, 1982;
Guigliano et al, 1982; Evans et al, 1982; Hiramatsu et al, 1987). Numerous
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mechanisms have been put forward to account for these changes, including,
reduction in plasma glucose per se (Jones et al, 1986), alteration in triglyceride
and free fatty acids levels due to enhancement of lipoprotein lipase activity (Sadur
and Eckel, 1982), the direct effect of hyperinsulinaemia on platelet metabolism
(Hiramatsu et al, 1986), and also possibly through platelet phospholipid changes
(Jones et al, 1983).
In this study, the platelets became more sensitive to the prostacyclin mimetic,
Iloprost. Janka and Demmel (1981), who studied a heterogeneous group of non-
insulin diabetic patients demonstrated that with improvement of glycaemic control
there was an increase in prostacyclin sensitivity mediated through raised cAMP
levels. However, this study showed that with improved glycaemic control there
was no significant difference between the Iloprost induced rises in platelet cAMP.
Therefore it is probable that the increase in Iloprost sensitivity occurred at a
later stage than the prostacyclin receptor adenyl-cyclase complex, and is perhaps
due to more efficient sequestration of internal free calcium.
This study has also shown that with improved glycaemic control there was a fall in
plasma RTG levels indicating that over this period there was a reduction in platelet
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activation. However, the platelets produced more TXB2 during aggregation and in
keeping with this there was a slight, but non-significant increase in the
aggregation EC50 for ADP, Reduced prostaglandin production from endogenous
platelet arachidonic acid (Janka and Demmel, 1981), along with reduced
thromboxane synthesis have been reported in diabetic patients (Tindall et al,
1981; Ylikorka et al, 1981). Jones et al, (1983) demonstrated reduced
arachidonic levels in the platelet membrane phospholipids of diabetic patients, and
this correlated negatively with the glycosylated haemoglobin. Therefore, the
increase in collagen-induced TXB2 production associated with improved glycaemic
control may be due to increased availability of arachidonic acid from membrane
phospholipids (Jackson et al, 1984).
It is well documented that there may be a deterioration in pre-existing
microangiopathy in the form of retinopathy after the institution of good diabetic
control (Steno Study Group, 1983; Kroc Collaborative Study Group, 1984;
Dandona et al, 1985; Dahl-Jorgensen et al, 1985), and the reason remains
unclear. Rapid improvement of glycaemia to normal may have a number of
pathogenic consequences. Firstly, it may reduce the retinal hyperperfusion which
is a characteristic of poorly controlled diabetes (Parving et al, 1983). Secondly,
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it significantly reduces the local concentration of glucose which is a major
substrate for retinal metabolism. In areas of retinal capillary closure just
maintained by diffusion from hyperperfusion and nutrient excess, the combination
of reduced perfusion and nutrient concentration, possibly induces retinal
deterioration (Keen, 1984). In addition, changes in platelets, for example
increased thromboxane production and increase in aggregability (Dandona et al,
1985), may also contribute. Indeed, some of the changes seen in this study are
consistent with platelet hyperaggregability contributing to the deterioration in
retinopathy associated with improved glycaemic control. Furthermore, Ihe
frequency of hypoglycaemia is increased in insulin-dependent diabetic patients
undergoing intensive improvement in glycaemic control (Steno Study Group,
1983). As described in chapter 9, hypoglycaemia itself can induce haemostatic and
haemodynamic changes which may contribute to further deterioration in
microvascular disease (Frier and Hilsted, 1985; Frier, 1986).
Alternatively, the changes described may simply reflect the maintenance of a
haemostatic balance. For example, platelets from mature rats have been
demonstrated to be more sensitive to prostacyclin as well as having increased
aggregability to collagen (Giana et al, 1985). It has been suggested that during ,
compensatory mechanisms operate to counteract increased platelet reactivity
(Giana et al, 1985). It is possible that in diabetic subjects undergoing
improvement of glycaemic control, a similar process occurs.
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Despite the heterogeneity in aetiology, the increased predilection for vascular
complications is not restricted to any one type of diabetes. Epidemiological
evidence in non-insulin-dependent diabetic patients suggests that fasting plasma
glucose levels above 6mmol/l are associated with a greater cardiovascular risk
(Eschwege et al, 1980), and that once levels are above 8mmol/l there is an
increased risk of developing diabetic retinopathy (Jarrett and Keen, 1976).
Furthermore, clinically important vascular lesions may be the presenting feature
in individuals who have relatively "mild" diabetes (Pirart, 1978; Kannel and
McGee, 1979) indicating that there may be a significant delay between the onset of
diabetes and diagnosis.
In this study the changes in platelet density profiles, intraplatelet (3-
thromboglobulin (6TG), plasma 8TG levels, intraplatelet cyclic AMP (cAMP)
levels, platelet release reaction, platelet thromboxane (TX)B2 production and
plasma fibrinogen levels have been investigated in 24 non-insulin-dependent
diabetic patients. These parameters were measured at diagnosis, after a 3-6 week
dietary run-in period, and again after 6 months on treatment with either
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metformin or gliclazide therapy.
7.2 Subjects
Twenty-four newly diagnosed, non-obese, non-insulin- dependent (age 54.3 ±
6.2 years; mean ± SD) diabetic patients and 12 comparably aged (52.6 ± 7.4
years) controls were studied. The patients had a body weight within the range 90 -
114% ideal (Metropolitan Life Insurance Tables), had normal renal function
(plasma creatinine <130 pmol/l; urine Albustix negative), had easily palpable
peripheral pulses and were non-smokers. None of the patients had evidence of
retinopathy. None were taking medication at entry into the study, particularly
significant aspirin ingestion was excluded by plasma aspirin levels at the entry
into and completion of the study. All patients had HbAi >9% at the end of the
dietary run-in period and were therefore randomized into either metformin
(Glucophage) or gliclazide (Diamicron) treatment groups, the drugs being given in
an open manner (Tables 1 and 2). For the study periods, patients were advised to
take a diet low in refined carbohydrate content, moderate in fibre and low in
saturated fat. The carbohydrate portion made up approximately 50% of the total
energy content. The patients were studied at diagnosis (Week -3/-6), 3 to 6
Table 7.1
Clinical details of the metformin-treated group at diagnosis (week -3/-6), at the
end of the dietary run-in period (week 0) and after 6 months on metformin
therapy (week 24)
Week -3/-6 Week 0 Week 24
Age (yrs) 53.1 (5.1) - -
Number of patients 12 (6M, 6F) - -
>
Fasting plasma glucose (mmol/l) 15.0 (3.1) 11.8 (3.1) 7.5 (1.7)
HbA-| (%) 14.3 (2.5) 12.1 (2.4) 7.4 (0.8)
BMI (kg/m2) 25.0 (1.4) 24.3 (1.4) 24.5 (1.6)
Plasma Cholesterol (mmol/l) 6.9 (1.1) 6.5 (0.9) 5.8 (0.7)
Plasma Triglyceride (mmol/l) 2.2 (0.9) 1.6 (0.5) 1.3 (0.4)
Values expressed as mean (SD)
Table 7.2
Clinical details of the gliclazide treated group at diagnosis (week -3/-6), at the
end of the dietary run-in period (week 0) and after 6 months on oral
hypoglycaemic therapy (week 24)
Week -3/-6 Week 0 Week 24
Age (yrs) 55.5 (5.1) - -
Number of patients 12 (6M, 6F) - - -
Fasting glucose (mmol/l) 14.2 (2.6) 12.2 (2.4) 6.4 (1.5)
HbA-| (%) 13.3 (1.4) 11.7 (1.5) 7.0 (0.8)
BMI (kg/m2) 23.7 (1.4) 23.1 (1.3) 23.6 (1.4)
Plasma Cholesterol (mmol/l) 7.5 (0.9) 7.0 (0.7) 6.3 (0.8)
Plasma Triglycerides (mmol/l) 2.3 (0.7) 1.9 (0.6) 1.6 (0.5)
Values expressed as mean (SD)
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weeks later at the end of dietary run-in period (Week 0) and again after 6 months
of oral hypoglycaemic therapy (Week 24).
7.3 Methods
7.3.1 Clinical Assessment
Fasting plasma glucose was measured using a Yellow Springs Glucose Oxidase
Analyser. Glycaemic control, assessed by glycosylated haemoglobin (HbA-|), was
measured using commercially available agar plates (Read et al, 1980) the normal
range between 6-8%. Fasting triglycerides and cholesterol levels were estimated
using standard laboratory techniques (Tables 1 and 2).
7.3.2 Platelet Density
Platelet density was measured by the same method described in chapter 4. Platelet
counts were performed using a Coulter counter.
7.3.3 Platelet granule content and plasma BTG levels
As a measure of electron-dense granules, platelet nucleotides (ATP/ADP) were
extracted from platelet-rich plasma with 1 vol of a solution of trichloroacetic acid
(10% wt/vol) and EDTA for 10 min at 4°C. Nucleotides were then assayed by the
method of Holmsen et al (1972) with the kit and reagents supplied by LKB (South
Croydon, UK). 6-thromboglobulin (BTG) was assayed by radioimmunoassay using
the method of Bolton et al (1976). The amount of BTG present in platelets, which
reflects platelet alpha-granule content was estimated after lysis of EDTA:PRP
(with known platelet count) with Triton X-100.
7.3.4 Platelet TXB2 production, release reaction, cAMP levels and plasma
fibrinogen
Platelet TXB2 production response to exogenous collagen (2 jig/ml) was measured
in duplicate using a standard double antibody technique as described in chapter 5
(Armstrong et al, 1985). Release of platelet dense granule constituents (5HT,
ADP) were measured using the radio-labelled isotope prelabelling technique
(Armstrong et al, 1985) and basal platelet cAMP and the rise in cAMP by PGE-|
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(0.2 fj.mol/1) were measured by a protein binding assay (Gilman, 1970;
Armstrong et al, 1985): the methods are all described in chapter 5. Fibrinogen
was measured using the Claus technique (1957)
7.3.5 Statistical analysis
Results are expressed as mean (SD) and the groups were compared using Students'
t-tests.
7.4 Results
Tables 7.1 and 7.2 summarise the biochemical profiles (fasting plasma glucose,
HbA-| and fasting plasma triglyceride and cholesterol) and body mass index at
diagnosis, after the dietary run-in period and after 6 months in the metformin-
and gliclazide- therapy groups. The dosages of metformin and gliclazide ranged




(a) Fasting plasma glucose
There was no difference in the fasting plasma glucose at diagnosis in the patients
randomised at week 0 from metformin and gliclazide therapy. In the two groups
there was a similar and significant reduction in the fasting plasma glucose during
the dietary run-in period (p <0.01), and after 6 months on metformin or
gliclazide therapy (p <0.001) (Tables 7.1 and 7.2).
(b) Glycosylated haemoglobin
Glycosylated haemoglobin in both groups fell during the dietary run-in period (p<
0.01) and again after 6 months on metformin or gliclazide therapy (p<0.001).
There was no significant difference in the HbA-| between the two groups at any of
the three study points (Tables 7.1 and 7.2).
7.4.2. Fasting serum cholesterol and triglycerides
There was no significant difference in the serum cholesterol and triglyceride levels
between the two groups at the time of diagnosis, at the end of the dietary run-in
periods or after 6 months on oral hypoglycaemic therapy. However, after the
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period on diet-alone therapy, there was a significant reduction in both serum
cholesterol (p<0.05) and serum triglyceride (p<0.05) with a further fall in
cholesterol (p<0.01) and triglyceride (p<0.05) after 6 months on oral
hypoglycaemic therapy (Tables 7.1 and 7.2).
7.4.3. Body mass index (BMI)
The group randomized to gliclazide had slightly lower BMI at the time of diagnosis
compared with those randomised to metformin (p<0.05). In both groups the BMI
fell during the diet-alone period (p<0.01), with the gliclazide group having a
slight but significant increase in BMI at the end of 6 months on therapy (p<0.05)
(Tables 7.1 and 7.2).
7.4.4. Platelet variables (Tables 7.3 and 7.4)
(a) Platelet Count
There was no difference in the platelet count between the diabetic and control
groups, and there was no change with therapy.
(b) Platelet Density
At diagnosis the two groups combined had increased platelet density compared with
the control group (78.8 (3.0) v 72.8 (2.6); p< 0.001). There was no significant
difference in the platelet densities between the two groups at diagnosis and there
was no significant change by week 0. However, in both the metformin and
gliclazide-treated groups there was a significant decrease in platelet density at
week 24 compared with the level at diagnosis (p<0.05).
(c) Platelet nucleotides (ATP/ADP ratio)
At diagnosis the diabetic groups had increased nucleotide ratio compared with the
control group (4.2 (0.9) v 1.7 (0.4); p<0.001). By the end of the dietary run-
in period there was reduction in the intraplatelet nucleotide ratio (p<0.001), with
a further reduction after 6 months of oral hypoglycaemic therapy (p<0.001).
(d) Intraplatelet BTG
At diagnosis the intraplatelet BTG was significantly higher in the combined diabetic
group than in the control group (118 (47) v 30 (8.3); p< 0.001). There was no
significant reduction at the end of the dietary run-in period. However, there was a
significant reduction after 6 months of oral hypoglycaemic therapy (p<0.001).
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(e) Plasma 6TG
At diagnosis the plasma 3TG was significantly higher in the combined diabetic
group than in the control group (62 (22) v 29 (9); p<0.001). This variable
was not measured at week 0. At the end of the 6 months on oral hypoglycaemic
therapy, there was a significant reduction compared with at diagnosis levels
(p<0.001).
(f) Platelet TXB2
There was no significant difference in the platelet TXB2 production in response to
exogenous collagen between the diabetic group at diagnosis and control group, and
there was no alteration with therapy.
(h) Platelet Release Reaction
There was no difference in the platelet release reaction between the diabetic and
control groups, and there was no change with therapy.
(i) Intraplatelet cAMP levels
There was no difference in the intraplatelet cAMP response to PGE-| at diagnosis or
after the dietary run-in period between the two groups. However, after 6 months
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of oral hypoglycaemic therapy there was a significant increase in levels in both
the metformin (p<0.001) and gliclazide (p<0.05) treated groups 5.
7.4.5. Fibrinogen
The plasma fibrinogen levels were increased in the two diabetic groups compared
with controls (3.6 (1.2 v 2.8 (0.7 mg/100ml; p< 0.005) and were not
significantly altered by therapy.
7.4.6. Side effects
Two patients experienced mild hypoglycaemic episodes on gliclazide and their
dosage was reduced. Four of the patients on metformin noticed transient feelings of
nausea and mild diarrhoea (2 patients) at the start of treatment, but symptoms
lasted only a few days. In order to minimise gastro-intestinal intolerance, the
dosage of metformin was increased slowly and the tablets were taken after meals.
Table 7.3
Platelet variables and serum fibrinogen levels in the control and metformin-treated
groups at diagnosis (week -3/-6), at the end of the dietary run-in period (week 0)
and after 6 months on metformin therapy (week 24).
Control Group Metformin Group
Week -3/-6 Week 0 Week 24
Platelet count





















































Figures expressed as mean (SD)
Platelet density expressed as (x-1) x 1000
See text for significance values
Table 7.4
Platelet variables and serum fibrinogen levels in the control and glicazide-treated
groups at diagnosis (week -3/-6), at the end of dietary run-in period (week 0) and
after 6 months on gliclazide therapy (week 24)
Control Group Glicazide Group























































Figures are expressed as mean (SD)
Platelet density expressed as (x - 1) x 1000
See text for significance values
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7.5 Discussion
This study confirmed that both metformin (Clarke and Campbell, 1977; Herman,
1979; Campbell et al, 1987) and gliclazide (Shaw et al, 1985; McAlpine et al,
1988) combined with a diet restricting intake of refined carbohydrate, are
effective in the treatment of non- insulin-dependent diabetes. Although the dietary
run-in period was effective in reducing both fasting plasma glucose and HbA-|
levels, none of the patients had HbA-| less than 9% at this stage, and therefore
there was no control diabetic group involved in the study. All patients could
therefore be regarded as "diet failures". It is feasible that, if the dietary run-in
period had been longer (ie 3 - 4 months), a small control group could have been
studied (UK Prospective Study, 1983). In both treatment groups, the fasting
plasma glucose and HbA-( levels were equally reduced at the end of the 6 month
period, and indeed the mean HbA-j level in both groups was within the normal range
(6 - 8%). Also in both groups, the plasma cholesterol and triglyceride levels fell
and it is likely that this, at least in part, was due to the modification in diet.
Although there were only small changes in BMI, metformin appeared to be more
effective in maintaining the reduced BMI.
This study also demonstrated that platelet abnormalities and increased fibrinogen
levels consistent with hypercoagability are present at diagnosis in non-insulin-
dependent diabetic patients (De Silva et al, 1979; Hughes et al, 1983; Peacock et
al, 1986). The platelets were denser, contained more alpha- and electron-dense
granules, and the increased plasma RTG was in keeping with increased in vivo
platelet activation (Betteridge et al, 1981). It is known that in non-diabetic
subjects, dense platelets differ from their lighter less dense cohorts in terms of
their content of glycolytic enzymes (Karpatkin, 1974), nucleotides (Booyse et al,
1968) and number of granules (White et al, 1972). In addition they adhere more
readily to collagen (Castellan and Steiner, 1976) aggregate more rapidly in 'the
presence of ADP (Karpatkin, 1978) and synthesise protein more actively
(Pennington et al, 1976). These dense cells are possibly more immature, and the
increase in the overall density of platelets at diagnosis in non-insulin-dependent
diabetic patients probably reflects the increased rate of platelet turnover that is
known to occur in diabetes (Jones et al, 1981; Tindall et al, 1981). With
restriction of the intake of refined carbohydrate, and also metformin and gliclazide
therapy, these platelet variables returned towards normal but only the platelet
density mean returned to within the normal range. Although gliclazide (Ponasi et
al, 1979; Violi et al, 1984) and metformin (Ferugilo et al, 1980; Gin et al,
1988) are reported to have specific effects on human platelets which may be
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independent of glycaemic control, they induced very similar platelet changes. In
addition, it is interesting to note that the most marked changes in platelet
parameters occurred over the 3-6 week period that the patients were on diet
therapy alone.
Platelets from diabetic patients have been demonstrated to have reduced sensitivity
to inhibiting prostaglandin (Betteridge et al, 1982) and the situation is possibly
aggravated in vivo by reduced vascular prostacyclin production (Johnson et al,
1979). Prostaglandin sensitivity is mediated through intraplatelet cAMP levels,
and the increase in intraplatelet cAMP with improved glycaemic control seen in
this study probably indicates slight increase in platelet prostacyclin sensitivity
with improvement in glycaemic control (Janka and Demmel, 1981). Although
platelets from insulin-dependent diabetic patients also have increased sensitivity
to prostacyclin with improvement of glycaemic control, as discussed in the
previous chapter, this is probably mediated through more efficient sequestration
of internal free calcium rather than changes in cAMP levels.
Although there was no significant change in platelet TXB2 production, there was a
trend towards an increase in production with improved glycaemic control, possibly
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occurring as a result of increased availability of arachidonic acid from membrane
phospholipids (Jackson et al, 1984). Similarly there was no difference or change
in platelet 5-hydroxytryptamine release, and this probably reflects that this is an
insensitive technique to measure platelet aggregation. As reported in previous
studies (De Silva, 1979; Cederholm-Williams et al, 1981), the plasma
fibrinogen level was elevated in the diabetic group, but there was no change with
treatment.
This study demonstrates that platelet abnormalities occur in non-insulin-
dependent diabetic patients which may over time contribute to the development of
vascular complications (Ganda, 1980; Colwell et al, 1983). These changes are
influenced by treatment, although it seems likely that improvement of glycaemic
control (Larkins et al, 1988), rather than any specific effect of the oral
hypoglycaemic agent employed, is the most important factor in returning these
parameters towards normality.
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8.4.3 Plasma neutrophil elastase and retinopathy
8.5 Discussion
8.1 Introduction
Recently, increased lysosomal content of neutrophil bactericidal proteins and
neutral proteases, have been described in diabetic patients (Oberg et al, 1986).
As discussed in earlier chapters, elastase, which is a neutrophil protease, can
cause endothelial damage directly (Harlan et al, 1985; Smedley et al, 1986), and
it has been suggested that it could contribute to the pathogenesis of vascular damage
(Robert et al, 1984). Futhermore, release of neutrophil elastase into the plasma
can be used to monitor neutrophil activation and degranulation (Weissman et. al,
1 980).
The aim of this study was to determine whether plasma (PNE) and/or total (TNE)
neutrophil elastase are increased in diabetic patients, and, if so, whether they are
associated with microvascular complications in the form of retinopathy.
8.2 Subjects
One hundred insulin-dependent diabetic patients (83 males, 17 females), aged
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29.8 ± 4.5 (mean ± SD; range 22-39) years, mean duration of diabetes 12.7 ±
6.6 (1-29) years and 35 comparable non-diabetic control subjects (25 males,
10 females; age 29.6 ± 4.0; range 22-38 years). No patient was known to have
active infection. Retinopathy was assessed after mydriasis and was graded as 0 =
nil, 1 = microaneurysms or dot haemorrhages only, 2 = exudative charge, 3 =
neovascularisation. All subjects were normotensive (BP < 140/90), had normal
renal function (plasma creatinine <120 p.mol/1, urine Albustix negative) had
easily palpable peripheral pulses, and were within 15% of ideal body weight
(Metropolitan Life Insurance Tables). Plasma glucose at the time of the study was
measured using a Yellow Springs Glucose Oxidase Analyser (Yellow Springs
Instrument Co Inc, Yellow Springs, Ohio, USA). Glycaemic control, as assessed by
total glycosylated haemoglobin, was measured by electrophoresis using
commercially available agar plates (Read et al, 1980), the normal range being 6-
8% (Table 8.1).
Table 8.1
Clinical data of diabetic patients and control subjects
Random
Duration plasma
Age of diabetes glucose HbA1 Retinopathy (n)
Groups (yrs) Sex (yrs) (nmol/l) (%) 0 12 3
Diabetic 29.8±4.5 83M 12.7±6.6 11.8±5.7 10.6±2.3 50 17 17 16
Patients (22-39) 17F (1 -29) (3.6-27.1 ) (6.5-1 7.0)
Control 29.6±4.0 25M -
Subjects (22-38) 10F




Peripheral venous blood (15ml) was collected in the morning in the non-fasting
state. A full blood count was performed using a Coulter PIusr (Coulter Electronics
Ltd, Luton, UK) and a differential leucocyte count was carried out manually on
blood films stained with May Grunwald/Geimsa.
8.3.2 Human neutrophil elastase assay
Venous blood for plasma neutrophil elastase (PNE) was anticoagulated with 31.2
g/l trisodium citrate in 50 g/l. Hepes buffer, while 10 ml/l Triton X-100 was
added for measurement of total neutrophil elastase (TIME). The sample for PNE was
centrifuged at 1500 g for 10 minutes at 4°C and the plasma was then aspirated.
Both plasma and lysed whole blood were stored at -20°C and assayed within a week
of sampling.
Human neutrophil elastase was measured by a specific radioimmunoassay using
rabbit polyclonal antiserum. The antigen was purified from human neutrophils
following leucapharaesis. The antibody was absolutely specific for neutrophil
elastase and did not cross react with pancreatic, monocyte or platelet elastase, but
measured neutrophil elastase equally well as the free enzyme or as a complex with
its inhibitors, alpha-1-proteinase inhibitor and alpha-2-macroglobulin (Greer
er al, 1989). In brief, 50 pi of standard/sample was added to 50 pi 125p
elastase (10 pg/l""1) and 50 pi anti-elastase antibody (dilution 1:3000) and
made up to 200 pi with buffer comprising 0.05 mol/l phosphate (pH 7.4), 0.6
mol/l Na CI, 2 mmol/l EDTA, 130 g/l heparin, 20 kll/l aprotinin and 2% beat
inactivated horse serum. Samples were incubated overnight at room temperature
and separated with donkey anti-rabbit immunoglobulin immobilised on Sepharose.
After shaking for 45 minutes at room temperature the bound complex was
separated from the free complex by sedimentation under gravity through a 10%
sucrose solution, then aspirated and counted on an NE 1600 gamma counter
(Nuclear Enterprises Ltd, Edinburgh, UK). Plasma neutrophil elastase and total
neutrophil elastase are expressed as ng/ml and, where relevant, as pg/106




Results are expressed as mean ± SD or mean (range) where appropriate. The full
blood and polymorph count from the diabetic patients and control subjects were
compared using two tailed unpaired Students' t-tests. Plasma neutrophil and total
neutrophil elastase from the diabetic retinopathy groups and control subjects were




The total white cell count was slightly, but not significantly increased in the
diabetic group when compared to controls. The neutrophil count was significantly
greater in the diabetic patients compared with the controls (P<0.02) (Table
8.2). However there was no difference in the neutrophil count between the
diabetic patients with early and no retinopathy (grades 0 and 1), compared with
those with exudative and proliferative retinopathy (grades 2 and 3).
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8.4.2 Neutrophil Elastase
Total neutrophil elastase was significantly greater in the diabetic group than in the
controls (p<0.02). Plasma neutrophil elastase was similarly elevated in the
diabetic subjects when compared with controls (p<0.001) (Fig 8.1 and Table 8.2).
Total neutrophil elastase (r = 0.68; p < 0.001), , but not plasma neutrophil
elastase showed a significant correlation with peripheral blood neutrophil count
(Figs 8.2 and 8.3). When corrected for the neutrophil count, total neutrophil
elastase did not differ between diabetic patients and control subjects.
There was no correlation between total neutrophil elastase or neutrophil elastase
and age, duration of diabetes, plasma glucose or HbAi.
8.4.3 Plasma Neutrophil Elastase and Retinopathy
Mean plasma neutrophil elastase was higher in diabetic patients with exudative and
proliferative retinopathy (34.98 ng/ml) than in those with little or no
retinopathy (25.54 ng/ml). After log transformation of the data, there was no
Table 8.2
White cell count and neutrophil count in the diabetic patients and control subjects.
White cell Neutrophil
Groups count(x109/l) count(x109/l)
Diabetic patients 7.31(2.07) 5.03(1.60)*
Control subjects 6.59(1.90) 4.33(1.48)
Values expressed as mean (SD).
* P < 0.05
Table 8.3
Plasma neutrophil and total neutrophil elastase in the diabetic patients and control
subjects
Groups
Plasma Neutrophil Total Neutrophil TNE/
Elastase(ng/ml) Elastase(ng/ml) Polymorph
(PNE) (TNE) count (jj.g/106)








Values expressed as median (range)
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significant difference between the two diabetic groups. However, of the 20 patients
with plasma neutrophil elastase greater than the mean ± 2SD of the control groups,
14 had exudative or proliferative retinopathy.
8.5 Discussion
As discussed in chapter 3, numerous abnormalities of leucocyte function have been
described in diabetes. These abnormalities include a reduction in neutrophil
killing (Wilson et al, 1986) phagocytosis, bactericidal capacity (Bagdade et al,
1974), and chemotaxis (Mowat and Baum, 1971; Fikrig et al, 1977). These
changes, together with local factors such as glycosuria and autonomic bladder
dysfunction (Sawers et al, 1986), contribute towards the increased susceptibility
to infection seen in diabetes (Bagdade, 1976; Gordon, 1983). Possibly as a
reflection of reduced neutrophil efficacy, this study demonstrates that young
insulin-dependent diabetic patients, in the absence of overt infection, have a
slightly higher neutrophil count than control subjects.
As discussed in earlier chapters, neutrophil elastase is a potent proteolytic enzyme
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which is present in high concentrations predominately in the azurophilic granules
of neutrophils and myeloid precursors (Janoff, 1985). The assay used in this
study is specific for human neutrophil eiastase. Polyclonal antiserum raised in
rabbits against purified human neutrophil eiastase does not bind to any other
neutrophil protein, and does not detect antigenically distinct elastases from
platelets, monocytes and pancreas. It does however, measure neutrophil eiastase
equally well in the free form and when complexed to its inhibitors alpha-1-
proteinase inhibitor and alpha-2-macroglobulin, the forms in which it circulates
in plasma. As neutrophil eiastase is largely concentrated in the azurophilic
granules of granulocytes, measurement of plasma eiastase concentrations provides
a marker of neutrophil azurophilic granule release in vivo (Janoff, 1985).
In addition total neutrophil eiastase content was increased and correlated strongly
with the number of circulating neutrophils. This result, therefore, does not
support the previous suggestion that the lysosomal content of eiastase is increased
(Oberg et al, 1986). In contrast there was no correlation between peripheral
neutrophil count and plasma neutrophil eiastase. This is consistent with the
elevation of plasma neutrophil eiastase reflecting increased neutrophil activation
(Janoff, 1985).
Neutrophils are a vital component of the normal inflammatory response and they
are now increasingly implicated in the pathogenesis of certain diseases (Malech and
Gallin, 1987; Epstein, 1989). Neutrophil granules contain a range of acid and
neutral proteases as well as cationic proteins which increase vascular
permeability (Campbell et al, 1982). Neutrophil elastase has a wide range of
substrates apart from elastin, for example collagen, immunoglobulin, fibrinogen,
complement and proteoglycans (Janoff, 1985). Its ability to degrade collagen and
vascular matrix proteins gives it a powerful potential to contribute to 4he
development of vascular damage. The vascular endothelium provides a surface onto
which neutrophils can adhere and release their granules directly (Harlan et al,
1985; Smedley et al, 1986). Neutrophil adherence is promoted by endothelial
damage and thus in diabetes neutrophil activation and release of neutrophil elastase
could occur as a primary phenomenon or alternatively, secondary to endothelial
damage due to diabetic angiopathy. The finding in this study that diabetic patients
have higher levels of plasma neutrophil elastase, supports the concept of
neutrophil-endothelial interaction in the development of diabetic microangiopathy
(Oberg et al, 1986). However it does not answer whether release of neutrophil
elastase is a primary or secondary phenomenon.
These results also suggest that in addition to the widespread haematological
abnormalities in platelets (Colwell et al, 1983), erythrocytes ( et al, 1982) and
in leucocyte function (Bagdade, 1976; Glass et al, 1987) already recognised in
patients with diabetes mellitus, there is also increased neutrophil activation and
release of neutrophil elastase which could contribute to the pathogenesis of
microvascular disease.
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The brisk counter-regulatory hormonal response to acute insulin-induced
hypoglycaemia in normal humans includes the secretion of catecholamines and
Cortisol (Garber et al, 1976) and these hormones induce a biphasic leucocyte
response with an initial rise in the total lymphocyte count followed by a later rise
in the granulocyte count (Frier et al, 1986; Fisher et al 1987). The rapid
mobilisation of lymphocytes is adrenergically-mediated (Frier et al, 1983;
Fisher et al, 1987), while the rise in neutrophils appears to be mediated
primarily by Cortisol (Corrali et al, 1980; Frier et al, 1986; Fisher et al,
1989). The secretion of catecholamines also causes haemoconcentration with a
reduction in plasma volume (Hilsted et al, 1985) which is associated with an acute
rise in blood haematocrit (Fisher et al, 1987), an increase in blood viscosity
(Neil et al, 1987), platelet activation (Kishikaw et al, 1987) and fibrinolysis
(Hutton et al, 1979; Dalsgaard-Nielson et a 1,1982; Trovati et al, 1986). It has
been suggested that when these changes are superimposed on established diabetic
microangiopathy, they may encourage intravascular coagulation, reduce capillary
blood flow, and precipitate capillary closure, thus aggravating the microvascular
complications of diabetes.
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As discussed in chapter 8, human neutrophil elastase has been implicated in
vascular damage, and total (TNE) and plasma (PNE) neutrophil elastase are
elevated in diabetic patients. The aim of this study was to determine whether
neutrophil activation manifested by a rise in plasma neutrophil elastase,
accompanies the leucocyte mobilisation which occurs in response to insulin-
induced hypoglycaemia in non-diabetic subjects, as this may have implications for
the contributory role of hypoglycaemic stress to the pathogenesis of diabetic
microvascular disease.
9.2 Subjects
Fifteen healthy male normal volunteers, aged 23-39 years were studied in a
supine position after an overnight fast. Smoking and the ingestion of caffeine was
prohibited for the preceding 12 hours. An intravenous cannula was inserted into
an antecubital vein, and after resting for 30 minutes basal blood samples were
taken. At time zero, hypoglycaemia was induced using soluble, human insulin
(Human Actrapid, Novo Laboratories, Basingstoke, UK) in the dosage of 0.125
149
units/kg body weight. Plasma glucose was monitored at the bedside at frequent
intervals using a glucose meter (Reflolux, BCL, Lewes, UK), and frequent
measurements of heart rate and blood pressure were made throughout the study.
9.3 Methods
9.3.1 Serial sampling
Serial blood samples for the measurement of plasma glucose were taken at frequent
intervals until 120 min after the acute autonomic reaction (R), which coincided
with the nadir of plasma glucose. Sampling was timed from R to account for
individual variability in the time of onset of acute hypoglycaemia after the
administration of insulin. Blood samples were taken for PNE and TNE at baseline,
R + 45 min and at R + 120 min.
Differential blood counts, and PNE and TNE estimations were undertaken as
described in chapter 8 .
9.3.2 Statistical Analysis
Results are expressed as mean (SD) or as median (range) where the data is not
normally distributed. The data from the three time points were compared using the
Wilcoxon rank sum test with the Bonferroni correction.
9.4 Results
9.4.1 Blood glucose, pulse and blood pressure changes
All subjects experienced an autonomic reaction (R) typical of acute hypoglycaemia
with sudden onset of sweating and a tachycardia at approximately approximately 20
(range 18-28) min after the administration of insulin. The plasma glucose fell
from a mean (SD) basal value of 4.6 (0.2) mmol/l to a nadir of 1.3 (0.2) mmol/l
(p< 0.01) which coincided with the onset of R, the acute autonomic reaction, with a
subsequent gradual recovery to basal values (Figure 9.1). The changes in pulse
and blood pressure were similar to those described previously in normal humans
in response to acute hypoglycaemia (Figures 9. 2 and 9. 3) (Frier and Hilsted,
1985; Frier, 1986).
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9.4.2 Leucocyte count and elastase levels
The neutrophil count rose from a median basal value of 3.4 (range 1.9 - 6.5) x
109/l to 10.7 (9.4 - 16.3) x 109/l at R + 120 min (p < 0.001) (Figure
9.4), while the total leucocyte count increased from 5.7 (4.1 - 8.1) x 109/l to
12.8 (11.3 - 18.6) x 109/l (p < 0.001) (Figure 9.5). The plasma neutrophil
elastase concentration rose from a basal value of 21 (12 - 34) ng/ml to 29 (14
- 70) ng/ml at R + 120 min (p< 0.05) with 11 out of 15 subjects having elevated
PNE concentration at R + 120 min. Two subjects had elevation of PNE at R + 45
min, which declined to sub-basal levels at R + 120 min. (Figure 9.6). There
was a pronounced rise in total neutrophil elastase from 5900 (3130 - 8200)
ng/ml to 25200 (23000 - 52500) ng/ml (p< 0.001) (Figure 9.7). A
correlation was observed between total neutrophil elastase concentration and
neutrophil count before the induction of hypoglycaemia (r = 0.739; p<0.001), but
no correlation was observed between the total neutrophil elastase and the
neutrophil count at either R + 45 min or R + 120 min. No correlation was found








Change in plasma glucose in response to hypoglycaemia. Resul
expressed as mean + SD. (Insulin = insulin injection; R = ti
of hypoglycaemic reaction).
Figure 9.2
Change in heart rate in response to hypcglycaemia. Results express
















0 \ ^ R
INSULIN
R+15 R+30 R+45 R+60
Changes in systolic, diastolic and mean blood pressure in response
to hypoglycaemia. Results expressed as mean + SD. (Insulin = insulin
injection; R = time of hypoglycaemic reaction).
Figure 9.4
NEUTOPHJL COUNT /-













~"T T \ I 1
To I R+45 R + 120
I
TIME (mins)
Change in polymorph count
(I = insulin injection, R
in response to hypoglycaemia

















R + 45 R + 120
Change in total leucocyte count in response to hypcglycaemia


















R + 45 R + 120
TIME (mins)
Change in plasma neutrophil elastase in response to hypoglycaemia.















To t R+45 R + 120
Change in total neutrophil elastase in response to hypoglycaemia.
(I = insulin injection, R = time of hypoglycaemic reaction).
159
9.5 Discussion
In healthy non-diabetic subjects insulin-induced hypoglycaemia is accompanied by
an abrupt increase in heart rate, a rise in systolic blood pressure, and a fall in
diastolic pressure (French and Kilpatrick, 1955; Lloyd-Mostyn and Oram,
1975), and cardiac output is increased by about 50% at the onset of hypoglycaemia
(Hilsted et al, 1984). Since the mean blood pressure falls only slightly, the
calculated total peripheral vascular resistance declines sharply during
hypoglycaemia. Vascular resistance is reduced mainly in muscle (Hilsted et- al,
1984; Middleton and French, 1974), but in other vascular areas such as the
hepatosplanchnic vascular bed it may be unchanged (Hilsted et al, 1984) or
decrease only slightly (Beattie et al, 1952). In the subcutaneous vascular bed,
vasoconstriction occurs in response to hypoglycaemia both in normal and in
diabetic subjects and persists for at least two hours after acute hypoglycaemia
(Hilsted et al, 1982). The cardiovascular changes result from stimulation of the
sympatho-adrenal system in response to hypoglycaemia and can be largely ascribed
to the release of adrenaline from the adrenal medulla, although the precise role of
sympathetic innervation remains undefined. It seems likely that vasoconstriction
prevails in some areas, although the integrated effect of hypoglycaemia on the
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circulation is reduction in vascular resistance (Frier and Hilsted, 1985).
Several parameters of haemostasis alter rapidly in response to acute insulin-
induced hypoglycaemia in both diabetic and non-diabetic subjects. These include a
rapid rise in factor VIII activity (Corrall et al, 1980), elevation of fibrinogen
concentration (Dalsgaard-Neilson et al, 1982), and enhancement of platelet
aggregation (Hutton et al, 1979; Hilsted et al, 1980). Plasma R-thromoglobulin
also increases in response to acute hypoglycaemia (Monnier et al, 1985)
reflecting increased platelet activation (Kaplan and Owen, 1981). The
enhancement of ADP-induced platelet aggregation provoked by hypoglycaemia is
associated with a reduction in the platelet count (Hilsted et al, 1980), which
further suggests intravascular aggregation. Platelet aggregation during
hypoglycaemia appears to be induced by the secretion of adrenaline, which appears
to promote aggregation through platelet alpha2-adrenoreceptors (Trovati et al,
1986; Kishikawa et al, 1987). In addition, acute hypoglycaemia provokes an
increase in the haematocrit, the erythrocyte count, and haemoglobin concentrations
(Frier et al, 1983; Hilsted et al, 1984). As the haematocrit is the principal
determinant of blood viscosity, this must also increase acutely in response to
hypoglycaemia, thereby influencing capillary blood flow in various vascular beds.
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Both hypercoagulability and increased blood viscosity have been implicated in the
development of microvascular disease in diabetic patients (Barnes et al, 1977;
Lowe et al, 1980).
In this study, a small but significant rise in plasma neutrophil elastase was
observed following hypoglycaemia demonstrating that activation of neutrophils
occurs in addition to their mobilisation (Frier et al, 1983; Fisher et al, 1987).
In addition, hypoglycaemia induced a marked rise in the total neutrophil elastase
with loss of the correlation which is usually observed between the neutrophil
elastase concentration and neutrophil count. The five-fold increment in total
neutrophil elastase was associated with only a three-fold increase in the
polymorph count, implying that the mobilised polymorphs have greater overall
content of elastase. As elastase is synthesised early in neutrophil development, this
observation suggests rapid mobilisation of a younger and less mature population of
cells (Gallin, 1984) in response to hypoglycaemia. Hypoglycaemia therefore,
through both an increase in neutrophil count and an elevation in elastase
concentrations, provides the potential for enhanced leucocyte-endothelial
interaction. Furthermore, with the plasma and neutrophil elastase concentration of
elastase remaining elevated for 3 hours following acute hypoglycaemia, the
potential for vascular damage persists long after the metabolic recovery from
hypoglycaemia. It is possible that insulin-treated diabetic patients who have
vascular damage and who are frequently exposed to hypoglycaemia, may have
increased vulnerability to the potentially adverse effects of this stress. In these
patients neutrophil activation and release of neutrophil elastase may be increased,
thus exacerbating pre-existing microvascular disease.
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Indirect experimental evidence has suggested that a free radical mechanism is
implicated in the development of vascular disease in diabetes (Jennings et al,
1987). However, the methods for measuring free radical activity have until
recently been unsatisfactory (Dormandy and Wickens 1984). Polyunsaturated
lipids are particularly sensitive to free radical attack inducing a shift of double
bonds to the diene-conjugated configuration (Di Luzzio 1968; Pryor, 1976).
Recently the main diene- conjugated compound in human plasma has been identified
as the non-peroxide isomer of linoleic acid, PL-9, 11-LA' (Cawood et al, 1983;
Iversen et al, 1984; Iversen et al, 1985). In addition, the concentration of this
isomer has been shown to vary independently of the main serum lipid classes
(Harrison et al, 1985).
The aim of this study therefore, was to measure both linoleic acid (PL-9, 12-LA)
and its diene-conjugated non-peroxide isomer (PL-9, 11-LA") by High
Performance Liquid Chromatography (HPLC) in a group of insulin-dependent
diabetic patients, and to investigate whether any abnormality demonstrated
correlated with microvascular disease in the form of retinopathy.
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10.2 Patients
Thirty-four insulin-dependent diabetic patients (22 males, 12 females) aged
30.6 ± 4.6 years (mean ± SD), mean duration of diabetes 17.4 ± 4.9 years and 35
comparable non-diabetic controls (25 males, 10 females) aged 29.6 ± 4.9 years
were studied. All subjects were normotensive (BP<140/90), and had normal
renal function (plasma creatinine <120 pmol/l, urine Albustix negative).
Retinopathy was assessed after mydriasis and was graded as 0 = nil, 1 =




Plasma glucose at the time of the study was measured using a Yellow Springs
Glucose Oxidase Analyser. Glycosylated haemoglobin, was measured by
electrophoresis using commercially available agar plates (Read et al, 1981), the
Table 10.1
Clinical data of diabetic patients and control subjects
Pqb Duration Plasma HBA-) Retinopathy groups
Groups (yrs) Sex of diabetes glucose (%)
(yrs) (mmol/l) 0 12 3
Diabetic 30.6 22M 17.4 12.2 11.1 0 7 13 14
Patients (4.6) 12F (4.9) (5.8) (2.3)
Control 29.6 25M -
Subjects (4.9) 10F
Values expressed as mean (SD)
For grading of retinopathy see text
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normal range being 6 - 8% (Table 10.1).
10.3.2 Leucocyte Count
Peripheral venous blood was collected in the morning in the non-fasting state.
Full blood count was performed using a Coulter PIusq (Coulter Electronics Ltd,
Luton, UK) and a differential leucocyte count was carried out manually on blood
films stained with May- Grunwald/Geimsa.
10.3.3 Assay of Diene Conjugates
Molar concentrations of phospholipid-esterified linoleic acid (PL-9, 12-LA) and
of phospholipid-esterified diene-conjugated isomer (PL-9, 11-LA') were
measured by the technique described by Iversen et al (1985). 0.5ml of plasma
was mixed with 0.5ml of a solution comprising 0.1 mol/l Tris (pH 8.9) 1 mol/l
methanol and 5000 yJ\ phospholipase f\2- The mixture was incubated at 25°C for
15 minutes, after which 2ml methanol containing 0.5% acetic acid and 50mg/l
beta-eleostearic acid [18:3 (9,11,13)] was added to precipitate the protein, and
the internal standard added. The preparation was then centrifuged and 2ml
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supernatant was applied to a "Bond Elut" column that immediately before use was
washed twice with 2.5ml propan-2-ol/acetonitrile 2:1 and conditioned twice with
2.5ml of a wash solution of methanol/water/acetic acid 67:33:0.04. The column
was again washed after the sample had been applied. The eluate was directly
injected into the HPLC by filling the sample loop. The conjugated dienes were
measured at 234nm and the non-conjugated fatty acid, linoleic acid, was measured
at 205nm.
HPLC was performed on Laboratory Data Control (Stone, Staffordshire, UK)
equipment which comprised a Constametic III pump and a Gibson spectromonitor III
variable wavelength ultraviolet (uv) detector and an autoanalyser (Cotati,
California, USA), which had a 50 pi sample loop. The column used was a
spherisorb OD52 250x4mm column containing 5 pm capped spherical particles
(Hichrom, Reading, Berks), and had a mobile phase of acetonitrate/water/acetic
acid 85:15:0.1 with a flow rate of 1.5ml/min.
10.3.4 Statistical analysis
Results are expressed as mean (SD). The data from the diabetic and control groups
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were analysed using two tailed unpaired Students' t-tests. Multiple regression
analysis was performed to assess the possible influences of the independent
variables, HbA-), and plasma glucose on the concentration of the diene-conjugate of
linoleic acid, PL-9,11-LA'.
10.4 Results
There were no differences in the total white count 7.5 (2.1) v 6.9 (1.9) x 109/l
and the neutrophil count 5.0 (1.5) v 4.3 (1.5) x 109/l between the diabetic and
control groups. There was also no difference in the molar concentrations of PL-9,
12-LA between the two groups 422 (129) v 402 (81) (imol/l. However, the
concentration of PL-9, 11-LA' was significantly reduced in the diabetic group
compared with the control group 15.6 (6.7) v 19.3 (3.9) pmol/l (P< 0.01);
with the molar ratio of PL-9, 11-LA' x 100/PL-9, 12-LA similarly reduced 3.8
(1.3) v 5.0 (1.6) (P< 0.005) (Figure 1). The concentration of PL-9, 11-LA',
and the ratio of PL-9, 11-LA' to the substrate PL-9, 12-LA in the 14 patients
with proliferative retinopathy were 15.6 (7.9) pmol/l and 3.7 (1.3)
respectively, and the values were not significantly different from those without




















































The concentration of linoleic acid (PL-9, 12-LA), its non-peroxide
diene-conjugated isomer (PL-9, 11-LA') and ratio of PL-9, 11-LA' to
PL-9, 12-LA in the diabetic patients and control subjects. Horizontal
bars indicate mean + SD. (*, p < O.Ol; **, p< 0.005).
and the concentration of PL-9, 11-LA'.
10.5 Discussion
Abnormalities of free radical activity have been implicated in the development of
diabetic complications, including vascular disease (Jennings et al, 1987; Croutch
et al, 1978; Paller et al, 1984) and cataract development (Srivastava and
Ansari, 1988). In addition, the pancreas has been shown to be particularly
susceptible to oxidative injury with the islet 6-cell being relatively deficient in
enzymes capable of scavenging reactive oxygen radicals (Asayama et al, 1984).
Isolated pancreatic cells exposed in vitro to the diabetogenic agent alloxan sustain
damage that is preventable by superoxide dismutase, catalase and hydroxyl radical
scavengers (Grankvist et al, 1979). There is also evidence that the ability of
alloxan to generate reactive oxygen radicals (including hydroxyl radicals) is the
primary determinant of its diabetogenic properties (Asayama et al, 1984;
Asayama et al, 1984). Futhermore, streptozotocin exerts diabetogenic properties
that, like alloxan, may be prevented by prior administration of superoxide
dismutase (Gandy et al, 1982), but its actions may not involve the direct
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formation of reactive oxygen radicals (Asayama et al, 1984). More recently, it has
been demonstrated that tissue antioxidant systems are altered in rats where
diabetes is induced by streptozotocin and that these changes are reversed by insulin
(Wohaeib and Godin, 1987).
A previous study measuring both oxidation and peroxidation of linoleic acid
demonstrated that the summation of these processes is increased in diabetes
(Jennings et al, 1987). In non-diabetics, it is recognised that the predominant
diene conjugate component of linoleic acid is PL-9, 11-LA' (Iversen et al, 1984).
However, this process may be altered in diabetics, and it seems likely that there is
a considerable shift to lipid peroxidation (Nishigaki et al, 1981). This reduction
in lipid oxidation could be explained by either diminished free radical activity, or
by competition between the lipid oxidation and peroxidation pathways. Lipid
peroxides themselves have been implicated in vascular endothelial damage (Blake
et al, 1985), and they are also intimately involved in prostaglandin biosynthesis;
they both stimulate cyclooxygenase and hence prostaglandin synthesis, and inhibit
prostacyclin production (Blake et al, 1985; Warso and Lands, 1983; Hemler et al,
1979). This increase in lipid peroxidation may in part explain the abnormalities
of platelet and endothelial function (Ham et al, 1979; Colwell et al, 1983) that
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have been implicated in the development of diabetic microvascular disease.
As discussed in Chapter 3, the origin of plasma free radical activity is uncertain,
although phagocytic cells which produce the free radical anion superoxide
particularly during phagocytic killing are a likely source (Nath et al, 1984;
Malech and Gallin, 1987). Superoxide is the product of a NADPH-dependent
membrane oxidase (Barbior, 1978), which in turn is dependent upon glucose-
induced aldose reductase activity. The reduction in bactericidal properties of
neutrophils from diabetic patients is due at least in part to the decrease in
superoxide production (Wilson et al, 1987), which probably reflects a change in
the redox potential within leucocytes secondary to abnormalities of the polyol
pathway (Wilson et al, 1987). An alternative explanation for the reduction in
free radical activity is increased antioxidant activity, in either serum or
membrane structures. However both glutathione and vitamin C, which are potent
antioxidants, have been demonstrated to be reduced in diabetic patients (Chari et
al, 1984; Jennings et al, 1987).
Although free radicals may have a role in the microenvironment of the vascular
endothelium, these results do not support the hypothesis that free radicals play a
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Although free radicals may have a role in the microenvironment of the vascular
endothelium, these results do not support the hypothesis that free radicals play a
significant role in the development of diabetic vascular disease. Indeed, if the
reduction in free radical activity is secondary to polyol pathway abnormalities, and
yet they do play a part in the development of diabetic vascular disease, treatment






Although microvascular disease will not occur in the absence of hyperglycaemia,
there is wide individual variation in the time of appearance and severity of
microvascular complications. For example, approximately one-third of patients
with insulin-dependent diabetes mellitus will develop severe complications,
whereas the other two-thirds run a more benign course (Deckert et al, 1978). In
addition, about 20% of insulin-dependent diabetic patients do not develop clinically
evident complications even after 40 years of diabetes, yet a small minority may
have severe problems after only five years without any obvious difference in
glycaemic control (Rosenstock and Raskin, 1988). It would seem likely that some
patients demonstrate a genetic susceptibility, although the relevant genetic
markers and their roles remain unresolved (Jennings and Barnett, 1988).
Previous studies in diabetes have demonstrated numerous abnormalities of platelet
and leucocyte function and also free radical activity. However, the results are
often inconsistent and conflicting. This has occurred, at least in part, because of
the heterogeneity of the groups of patients studied and the diverse methods used. In
addition, conclusions are often inferred from indirect methods. Furthermore,
studies tend to investigate only one aspect, while it seems likely that there is
considerable interaction between platelet, leucocyte, endothelial and hormonal
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abnormalities (Stout, 1979; Ganda, 1980; Colwell et al, 1983; Oberg et al,
1 986).
The work in this thesis supports the concept of platelet and leucocyte activation
contributing to the development of diabetic microvascular disease. In the majority
of studies described, the microvascular complication, retinopathy, has been
investigated. As far as possible, the diabetic patients have been clinically free of
macrovascular disease, as it is probable that the underlying aetiopathogenesis for
macrovascular disease is quite different. In addition, the insulin- and non-
insulin-dependent diabetic patients studied have been in homogeneous groups and
have been investigated using modern methodology. The platelet abnormalities
demonstrated include changes in density, increased thromboxane production and
sensitivity, and decreased sensitivity to prostacyclin. These abnormalities, along
with the other changes in platelet function demonstrated, are consistent with the
hypercoagulable state that exists in diabetes. Although there were subtle
differences in the changes shown in insulin-dependent diabetes compared with
non-insulin-dependent diabetes, it is presumed that the underlying
aetiopathogenesis is similar for the two types of diabetes.
180
The increase in neutrophil elastase levels demonstrated, particularly during
insulin-induced hypoglycaemia, is also consistent with leucocyte-endothelial
interaction contributing to diabetic microvascular disease. Although the plasma
level of free radical activity, as shown by the level of the diene-conjugate of
linoleic acid (PL-9, 11-LA"), was not increased in insulin-dependent diabetes,
abnormalities of lipid metabolism related to free radical activity may still
contribute to diabetic microvascular disease. Furthermore, as discussed in
Chapter 10, the possible shift to lipid peroxidation in diabetes may interfere with
prostaglandin biosynthesis, resulting in altered platelet and endothelial function.
In addition, lipid peroxidation may also interfere with the action of alpha-1-
proteinase inhibitor, thereby increasing the potential for neutrophil elastase to
cause vascular damage.
Why abnormalities of platelet, leucocyte and endothelial function should occur in
diabetes remains unclear. Furthermore, it remains to be resolved whether the
changes occur as a primary phenomenon or, alternatively, secondary to endothelial
damage due to diabetic microvascular disease. It would seem likely, however, that
although some of the abnormalities result from vascular disease, the majority
contribute to and aggravate diabetic vascular disease (Colwell et al, 1983).
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There appear to be two possible general pathophysiological mechanisms by which
hyperglycaemia leads to irreversible tissue damage. A major consequence of
hyperglycaemia is excessive non-enzymatic glycosylation of proteins (NEG) (Eble
et al, 1983; Brownlee et al, 1984; Kennedy and Baynes, 1984). The initial step
in NEG is rapid and reversible, and results in the formation of a Schiff base. This
is followed by a slow rearrangement to a more stable ketoamine linkage (the
Amadori rearrangement). With further reactions and rearrangements beyond the
Amadori product, advanced glycosylation end-products accumulate (Monnier et al,
1984) causing increased cross-linkage of proteins such as collagen (Figure
11.1). In connective tissue, brown fluorescent pigments appear (Monnier et al,
1986) and collagen exhibits decreased susceptibility to in vivo and in vitro
proteolysis (Lubec and Pollak, 1980) with increased stiffness and thermal
stability (Andreassen et al, 1981; Sternberg et al, 1985). Although circulating
cells have considerably shorter half-life than collagen it seems likely that they are
affected by NEG leading to possible alterations in function. In particular, changes
in platelet and leucocyte enzyme activity along with binding of regulatory
molecules may result from NEG (Brownlee et al, 1984). In addition, relevant to
platelet behaviour, collagen extracted from placentae of diabetic patients has
increased ketoamine-linked glucose, and such collagen exhibits increased platelet-
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aggregating ability (Le Pape et al, 1983).
The other major consequence of hyperglycaemia is induction of altered steady-state
levels of intracellular metabolites. Aldose reductase and sorbitol dehydrogenase
form the two-step sorbitol pathway through which glucose is converted to fructose.
In the first step aldose reductase utilizes NADPH to catalyse the stereospecific
reduction of glucose to sorbitol (Figure 11.2). In most tissues the cellular
accumulation of sorbitol is negligible; however in diabetes, increased intracellular
concentrations of sorbitol lead to adverse effects, including increased osmotic
activity, especially in the lens, causing increased influx of fluid and changes in
membrane permeability, and subsequent onset of cellular pathology (Kinoshita,
1974; Stribling and Perkins, 1986). Increased levels of sorbitol are also
associated with a parallel decreased concentration of myo-inositol, and altered
cellular redox potentials result from the rapid depletion of NADPH (Gonzalez et al,
1984; Greene et al, 1987). In relation to diabetic vascular disease, abnormalities
of the polyol pathway have been particularly implicated in basement membrane
thickening (Kador and Kinoshita, 1985) and increased vascular permeability
(Lightman et al, 1987). Consistent with this concept, in animal models elevation
of the plasma level of the isomer of glucose, D-galactose, can induce changes in the
polyol pathway (Figure 11.2). This may reproduce many of the effects of diabetes
Figure 11.1
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on peripheral nerves, lens, cornea and retina (Datiies et al, 1983; Kinoshita,
1974; Engerman and Kern, 1984).
Diabetic microvascular disease clearly results from highly complex events, which
appear to be regulated by an array of environmental and possibly genetic
influences (Ganda, 1980). Full understanding of the role of the many factors
involved will only be achieved by long-term prospective studies following patients
from the onset of disease to the development of complications. These studies would
give greater insight if they included intervention limbs. At the present time,-the
main clinical method for delaying the onset of diabetic vascular disease, is the
maintenance of good glycaemic control. Indeed it has been demonstrated that
improving metabolic control to produce "near-normoglycaemia" may retard or
arrest the progression of diabetic microangiopathy (Hanssen et al, 1986).
Unfortunately, good glycaemic control is often associated with loss of
"hypoglycaemic awareness" (Lager et al, 1986, Amiel et al, 1987), and
continuous subcutaneous insulin infusion can be complicated by hyperkalaemia and
ketoacidosis (Hanssen et al, 1986). In addition, particularly as a result of
"hypoglycaemic unawareness", very "tight" glycaemic control can not be applicable
to all patients.
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Non-steroidal anti-inflammatory drugs have been shown to delay the onset of and
to decrease the rate of progression of microvascular disease (Powell and Field,
1964; Colwell et al, 1986; Donadio et al, 1988; The Damad Study Group, 1989).
The anti-prostaglandin agents studied lacked specificity and they probably effect
both TXA2 and PGI2 synthesis. It is probable that a specific thromboxane
synthetase inhibitor may be more appropriate, and consistent with this a
thromboxane synthetase inhibitor has been shown to reduce microalbuminuria in
insulin-dependent diabetic patients (Barnett et al, 1984).
In addition, antioxidants protect against free radical damage. The nutritional
antioxidants vitamin C and E are reduced in diabetes, and the increase in dietary
intake may be of therapeutic advantage and also allow for the further evaluation of
the role of free radicals in the pathogenesis of microangiopathy (McCarthy and
Rubin, 1984).
Aldose reductase inhibitors have been extensively investigated in both animal
models of vascular complications and in human diabetes. As suggested in Chapter
10, aldose reductase inhibitors may increase free radical activity. However,
through NADPH-sparing effects, there may be an increase in antioxidant reserve
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allowing tissues to be better able to deal with oxidative stress (Barnett et al,
1986).
Recently it has been reported that aminoguanidine, a nucleophilic hydrazine
compound, prevented both the formation of fluorescent advanced glycosylation end-
products and the formation of glucose-derived collagen cross-linking both in vitro
and in vivo (Brownlee et al, 1986). This compound prevents protein browning
and also the generation of superoxide radicals (Jones et al, 1986). Therefore,
aminoguanidine or a similar compound, may be important in the investigation of
the role played by extensive glycosylation-induced protein cross-linking in the
development of microangiopathy.
The use of specific therapeutic intervention, that does not rely solely on producing
near-normoglycaemia, could therefore be of therapeutic importance.
Furthermore, this form of intervention would probably lead to greater
understanding of the aetiopathogenesis of diabetic microvascular disease.
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